

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Prevalence of SARS-CoV-2 infection among the Brazilian Amazon indigenous populations

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054271
Article Type:	Original research
Date Submitted by the Author:	08-Jun-2021
Complete List of Authors:	Lima, Carlos Neandro ; Universidade Federal do Para Abreu, Isabella; Universidade Federal do Pará Rodrigues, Eliene Putira; Universidade Federal do Para Freitas, Vanessa; Universidade Federal do Pará Botelho, Bruno José ; Universidade Federal do Para Souza, Sandra; Universidade Federal do Para Cayres-Vallinoto, Izaura; Universidade Federal do Para Guerreiro, João; Universidade Federal do Para Ishak, Ricardo; Universidade Federal do Para Vallinoto, Antonio; Universidade Federal do Para
Keywords:	COVID-19, EPIDEMIOLOGY, INFECTIOUS DISEASES

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Prevalence of SARS-CoV-2 infection among the Brazilian Amazon indigenous**  
4  
5  
6  
7 **populations**  
8  
9  
10  
11  
12  
13

14 Carlos Neandro Cordeiro Lima,<sup>1</sup> Isabella Nogueira Abreu,<sup>1</sup> Eliene Putira Sacuena

15  
16  
17 Rodrigues,<sup>2</sup> Vanessa de Oliveira Freitas,<sup>1</sup> Bruno José Sarmiento Botelho,<sup>1</sup> Sandra

18  
19  
20 Souza Lima,<sup>1</sup> Izaura Maria Vieira Cayres Vallinoto,<sup>1</sup> João Farias Guerreiro,<sup>\* 2</sup> Ricardo

21  
22  
23  
24 Ishak,<sup>\*1</sup> Antonio Carlos Rosário Vallinoto<sup>\*1</sup>  
25  
26  
27  
28  
29  
30

31 <sup>1</sup> Laboratório de Virologia, Instituto de Ciências Biológicas da Universidade Federal do  
32  
33  
34 Pará, Belém, PA, Brasil;

35  
36  
37  
38 <sup>2</sup> Laboratório de Genética Humana e Médica, Instituto de Ciências Biológicas da  
39  
40  
41  
42 Universidade Federal do Pará, Belém, PA, Brasil.  
43  
44  
45  
46  
47  
48

49 \* RI, JFG and ACRV are senior authors of the manuscript  
50  
51  
52  
53  
54  
55

56 **Correspondence to Dr. Antonio Carlos Rosário Vallinoto; [vallinoto@ufpa.br](mailto:vallinoto@ufpa.br)**  
57  
58  
59  
60

## ABSTRACT

**Objectives** The emergence of SARS-CoV-2 and its spread at a pandemic level generated a serious warning over the impact of the infection on vulnerable indigenous populations of the Brazilian Amazon. Thus, the present study aimed to perform seroepidemiological survey for antibodies anti-SARS-CoV-2 in those populations.

**Methods** We performed a cross-sectional study to investigate the prevalence of anti-spike (S1) IgG antibodies among six indigenous ethnic groups living in the State of Pará (Northern Brazil). The villages of Xikrin do Bacajá, Assurini, Araweté, Parakanã, Munduruku and Kararaô were visited from October 2020 to January 2021 and 1,185 individuals, of both sexes, were enrolled in the investigation. Sera were tested for the presence of anti-SARS-CoV-2 IgM and IgG antibodies using two assays (a lateral flow rapid test and an ELISA assay).

**Results** The prevalence of IgM and IgG antibodies was 6.9% and 68,3%, respectively, ranging from 0 to 79.6% with significant differences between ages in two communities

1  
2  
3 (Araweté and Munduruku) and a case fatality rate of 0.86%. Herd immunity was  
4  
5  
6  
7 probably attained but the presence of IgM positivity showed ongoing cases.  
8  
9

10 **Conclusion** SARS-CoV-2 was rapidly spread among the indigenous populations  
11  
12 investigated, but it carried a low mortality. It is necessary to expand the serological  
13  
14 investigations towards other communities in the Amazon region of Brazil.  
15  
16  
17  
18  
19  
20  
21  
22  
23

24 **Keywords:** SARS-CoV-2, COVID-19, Indigenous peoples, Amazon.  
25  
26  
27  
28  
29  
30

### 31 **Strengths and limitations of this study**

32  
33

- 34 • Our previous reports called the attention to the distinct cultural and health  
35 aspects of the Amazonian peoples, the impact of the virus among native peoples,  
36  
37 and the importance of performing seroepidemiological surveys among vulnerable  
38  
39 populations.  
40  
41  
42  
43  
44  
45  
46  
47
- 48 • The results showed that SARS-CoV-2 infection reached the different indigenous  
49  
50 peoples living in the Brazilian Amazon region in an almost homogeneous way.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- The results highlight that SARS-CoV-2 infection hit the indigenous populations as rapidly as the virus entered the Amazon region, without the predicted mortality.
- The high IgG prevalence suggest the herd immunity was probably attained but the presence of IgM positivity showed ongoing cases.
- Furthermore, seroepidemiological surveys are of paramount importance for monitoring the outcome of the national contingency plan for the prevention and control of the epidemic.

## INTRODUCTION

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the first cases of Coronavirus Diseases 2019 (COVID-19) were reported by November 2019, in Wuhan, China.<sup>1</sup> The rapid spread of the virus determined its classification as pandemic by WHO<sup>2</sup> and because of the high morbimortality it highlighted the burden to vulnerable populations, including native indigenous peoples living in the Brazilian Amazonian who are susceptible to the virus and could be devastated by their immunological frailty.<sup>3-6</sup>

1  
2  
3  
4 Two previous reports from our laboratory calls the attention to the distinct cultural and  
5  
6  
7 health aspects of the Amazonian peoples, the impact of the virus among native peoples,  
8  
9  
10 and the importance of performing serosurveys among these groups to determine the  
11  
12  
13  
14 spectrum of the illness among them.<sup>57</sup>  
15  
16  
17  
18  
19  
20

## 21 METHODS

22  
23  
24 In 2020, a large cross-sectional seroepidemiological surveillance among indigenous  
25  
26  
27 ethnic groups within Para State (Northern Brazil, Amazon), started to investigate the  
28  
29  
30 prevalence of anti-SARS-CoV-2 IgM and IgG antibodies and the impact of the virus on  
31  
32  
33 the health of communities. The study was approved by the leaders of the communities  
34  
35  
36 and by the National Research Ethics Committee (*Comissão Nacional de Ética em*  
37  
38  
39 *Pesquisa* – CONEP; CAAE: 33470020.0.1001.0018), in accordance with the  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Declarations of Helsinki.

From October 2020 to January 2021, multiprofessional health care expeditions were  
prepared, composed by our team, the staff of the Health Department of the State of  
Para (*Secretaria de Saúde do Estado do Pará – SESPA*) and the Special Indigenous



1  
2  
3 Health Districts of Altamira and Santarém (*Distrito Sanitário Especial Indígena – DSEI*)  
4  
5  
6  
7 of the Special Secretariat of Indigenous Health (*Secretaria Especial de Saúde Indígena*  
8  
9  
10 – *SESAI-MS*). Six ethnic groups were visited while presenting active cases of COVID-  
11  
12  
13  
14 19, before starting the vaccination campaign among indigenous communities.  
15

16  
17 The groups investigated were from the Tupi (Asurini do Koatinemo, Araweté, Parakanã,  
18  
19 and Munduruku) and Jê (Xikrin do Bacajá and Kararaô) linguistic trunks. The groups are  
20  
21 geographically located in the State of Pará, Northern of Brazil (Figure 1). The Araweté is  
22  
23  
24 located at the margin of the Ipixuna stream, a tributary of the right margin of the Middle  
25  
26  
27 Xingu. Asurini is situated on the banks of the Igarapé Ipiaçava, a tributary of the right  
28  
29  
30 bank of the Xingu. Kararaô is also at the margin of the Xingu stream. Parakanã and  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Jacareacanga).

52 The investigation included 1,185 individuals of both sexes (552 male and 633 female),  
53  
54  
55  
56  
57  
58  
59  
60  
randomly selected from the Araweté (n=508), Asurini (n=08), Munduruku (n=317),

1  
2  
3 Parakanã (n=210), Xikrin (98) and Kararaô (n=44). All individuals were clinically  
4  
5  
6  
7 evaluated and a blood sample (5 mL) was drawn to test for the presence of anti-SARS-  
8  
9  
10 CoV-2 IgM and IgG antibodies.

11  
12  
13  
14 The prevalence of anti-SARS-CoV-2 IgG and IgM antibodies used a rapid test (lateral  
15  
16  
17 flow method; Guangzhou Wondfo Biotech Co., China) and an enzyme-linked  
18  
19  
20 immunosorbent assay (ELISA; Anti-SARS-CoV-2 S1 IgG, Euroimmun, Brazil),  
21  
22  
23 according to the manufacturer's recommendation.  
24  
25  
26  
27  
28  
29  
30

### 31 **Patient and public involvement**

32  
33  
34  
35 Neither patients, parents nor the public were involved in the design, conduct or reporting  
36  
37  
38 of this research.  
39  
40  
41  
42  
43  
44

## 45 **RESULTS**

46  
47  
48 Anti-SARS-CoV-2 IgG was detected among 503 (68.3%) individuals by the rapid test  
49  
50  
51 and 815 (68.8%) when tested by the ELISA (Table 1). Eight Asurini did not show  
52  
53  
54  
55 antibodies, but among the other villages, it ranged (by the Elisa test) from 51.7%  
56  
57  
58  
59  
60

1  
2  
3 (Munduruku) to 79.5% (Araweté and Kararaô). No statistical significance was observed  
4  
5  
6  
7 between the tests. It is worth mentioning that IgM antibodies detected among 51 (6.9%)  
8  
9  
10 individuals from three villages. There was no statistical significance of prevalence  
11  
12  
13 values according to sex ( $\chi^2= 0.001$ ;  $p=0.9793$ ), but in the Araweté the frequencies were  
14  
15  
16 significantly lower among those >31 years old ( $p=0.0065$ ) and in the Munduruku a lower  
17  
18  
19 frequency among those <6 years old and greater ( $p<0.0001$ ) among those older than 31  
20  
21  
22  
23  
24 years old (Table 2).  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1.** Prevalence of anti-SARS-CoV-2 (S1) IgG antibodies among Indigenous villages

Population	Age range	Sex		Rapid Test results			ELISA IgG anti-Spike S1 results			N Deaths		
		Male N (%)	Female N (%)	N tested	Negative N (%)	IgM N (%)	IgG N (%)	N tested	Negative N (%)		Ind N (%)	IgG N (%)
Xikrin do Bacajá <sup>[7]</sup>	02 a 84	51 (52.0)	47 (48.0)	95	38 (40)	nt	57 (60)	98	25 (25.5)	0 (0)	73 (74.5)	01
Asurini	17 a 42	0 (0)	8 (100)	0	nt	nt	nt	08	7 (87.5)	1 (12.5)	0 (0)	0
Araweté	8m a 84	258 (50.8)	250 (49.2)	236	29 (12.3)	11 (4.7)	196 (83)	508	92 (18.1)	12 (2.4)	404 (79.5)	0
Parakanã	7m to 95 y	106 (50.5)	104 (49.5)	195	06 (3.1)	39 (20)	150 (76.9)	210	65 (30.9)	06 (2.8)	139 (66.2)	01
Munduruku	7 m to 89 y	116 (36.6)	201 (63.4)	166	96 (57.8)	nt	70 (42.2)	317	139 (43.9)	14 (4.4)	164 (51.7)	05
Kararaô	1 a 94	21 (47.7)	23 (52.3)	44	13 (29.5)	1 (2.3)	30 (68.2)	44	9 (20.4)	0 (0)	35 (79.5)	0
Total	7m a 95 y	552 (46.6)	633 (53.4)	736	182 (24.7)	51 (6.9)	503 (68.3)	1,185	337 (28.4)	33 (2.8)	815 (68.8)	07

M (months); Y (years), nt (not tested); [7] Rodrigues et al. (2021); Ind: Indeterminate

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

**Table 2.** Age and sex distribution to anti-SARS-CoV-2 (S1) IgG antibodies among Indigenous villages

Age	Xikrin <sup>[7]</sup>		Asurini		Araweté		Parakanã		Munduruku		Kararaô		Total n/ total (%)
	male	female	male	female	male	female	male	female	male	female	male	female	
0-6	5	2	0	0	44	27	10	6	7	6	3	1	111/1,185 (9.4)
>6 a 16	15	11	0	0	61	56	18	18	8	17	6	8	218/1,185 (18.4)
>16 a 31	9	13	0	0	56	66	12	21	14	44	2	6	241/1,185 (20.3)
>31	10	8	0	0	45	49	27	27	26	42	3	6	243/1,185 (20.5)
*not informed	0	0	0	0	0	0	0	0	1	1	0	0	2/1,185 (0.2)
Total	39	34	0	0	206	198	67	72	55	109	14	21	815/1,185 (68.8)

[7] Rodrigues et al. (2021); Age distribution: (Overall:  $\chi^2=8.2$ ;  $p=0.042$ ); (Xikrin:  $G=7.8$ ;  $p=0,0514$ ); (Araweté:  $\chi^2=12.3$ ;  $p=0.0065$ ); (Parakanã:  $\chi^2=3.9$ ;  $p=0.2753$ ); (Munduruku:  $\chi^2=23.8$ ;  $p<0.0001$ ); (Kararaô:  $G=4.4$ ;  $p=0.2213$ ). G - G test;  $\chi^2$  - Qui-square.

1  
2  
3  
4  
5  
6  
7 The main clinical manifestations reported among infected individuals were coughing,  
8  
9  
10 dyspnea, coryza, fever, fatigue, diarrhea, ear pain, headache, chest and back pain.  
11  
12

13  
14 There were seven deaths among the 815 infected persons showing a case fatality rate  
15  
16  
17 of 0.86%.  
18  
19  
20  
21  
22  
23

## 24 DISCUSSION

25  
26  
27 Introduction of new infectious agents among vulnerable indigenous peoples is thought  
28  
29  
30 to be a heavy burden because of the low genetic variability among genes that control  
31  
32  
33 the immune response,<sup>8</sup> an important element working as a selective pressure over  
34  
35  
36 indigenous peoples since the initial colonization process of the Amazon region of Brazil.  
37  
38  
39 SARS-CoV-2, brought the question again as to how the virus would affect native  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

1  
2  
3  
4 Most of the indigenous peoples of the Amazon region of Brazil, including those of the  
5  
6  
7 present study, present endemic diseases as malaria, tuberculosis, virus hepatitis and, to  
8  
9  
10 HTLV-2 hyperendemic infections among Xikrin, Kararaô, Munduruku and Parakanã.<sup>9</sup>  
11  
12  
13  
14 Presently, there is no scientific evidence for host modulation of SARS-CoV-2 in the  
15  
16  
17 presence of these coinfections. Environmental and social conditions are important  
18  
19  
20 factors that could impact on COVID-19 among indigenous communities,<sup>3 4</sup> including the  
21  
22  
23 lack of drinking water and malnutrition, which might had been potentialized after the  
24  
25  
26 prophylactic isolation measures.  
27  
28  
29

30  
31 In a previous report the quality of tests to measure the presence of antibodies was  
32  
33  
34 raised.<sup>7</sup> It is important that antibodies to SARS-CoV-2 are detected using tests with  
35  
36  
37 greater sensitivity and specificity to obtain accurate prevalence rates. Rapid tests show  
38  
39  
40 low sensitivity and yield false negative results and false-positive results due to cross-  
41  
42  
43 reactions. Two methodologies were used and the results obtained were not significantly  
44  
45  
46 different.  
47  
48  
49

50  
51  
52 In contrast to the genetic and socio-environmental vulnerability the results showed  
53  
54  
55 SARS-CoV-2 infection evenly distributed, with a high prevalence of the virus and few  
56  
57  
58

1  
2  
3 reported deaths, confirming the official results by SESAI in its COVID-19

4  
5  
6  
7 epidemiological bulletin.<sup>10</sup>

8  
9  
10 The prevalence of anti-SARS-CoV-2 IgG antibodies shows a high dissemination of the

11  
12  
13 virus spread favored by inherent social and cultural difficulties of keeping social

14  
15  
16 distance, sharing households with other families and wearing masks correctly. In spite

17  
18  
19 of the high prevalence of infection, during the investigation they were still facing the

20  
21  
22 epidemic, showed by the detection of IgM antibodies in three villages. It is relevant to

23  
24  
25 mention that three villages are more than 100Km apart from each other and there is no

26  
27  
28 simple way of communication among them. This raises another important question in

29  
30  
31 regard to herd protective immunity. Apparently, the communities achieved herd

32  
33  
34 immunity levels,<sup>11</sup> similarly as found in Manaus, the capital of the Amazonas State.<sup>12</sup>

35  
36  
37 However, differently from what is seen among urban areas,<sup>13</sup> virgin soil epidemics

38  
39  
40 generally exhaust susceptible individuals before it comes to an end,<sup>14</sup> and the present

41  
42  
43 epidemic is still not totally explained and understood.

44  
45  
46 The results show new information over the SARS-CoV-2 epidemic among indigenous

47  
48  
49 peoples and provides the Brazilian government with tools to establish adequate



1  
2  
3  
4 measures to control the epidemic among Brazilian indigenous communities in the  
5  
6  
7 Amazon region.  
8  
9

## 10 CONCLUSION

11  
12  
13  
14 SARS-CoV-2 infection reached the indigenous populations from the State of Para as  
15  
16  
17 rapid as the virus entered the Amazon region, confirming our previous alert to the need  
18  
19  
20  
21 of serological studies for surveillance, minimizing the burden of the epidemic and to  
22  
23  
24 promote indigenous health policies.  
25

26  
27  
28 In spite of the suggestion of high mortality and chaos facing the Amerindian populations  
29  
30  
31 (*6*), the majority of the cases was asymptomatic or mild, with low fatality rate, supporting  
32  
33  
34 analysis that shows that the mortality associated with epidemics following contact of  
35  
36  
37  
38 Amazonian indigenous communities with urban communities has decreased in recent  
39  
40  
41 years.<sup>15</sup>  
42  
43  
44

45 Finally, continuing seroepidemiological surveys are of paramount importance for  
46  
47  
48 monitoring the outcome of the national contingency plan for the prevention and control  
49  
50  
51 of the epidemic, by a mass vaccination program for indigenous peoples started by  
52  
53  
54  
55 February 2021.  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7 **Acknowledgments** We thank the Indigenous populations for authorizing the study and  
8  
9  
10 the institutions that provided technical support for the development and implementation  
11  
12  
13 of this study. Our especial gratitude to Vilson Monteiro and Hailton Monteiro for  
14  
15  
16 laboratorial assistance during the expeditions to Indigenous villages.  
17  
18  
19  
20  
21  
22  
23

24 **Contributor** ACRV, JFG and RI: conception of idea, data analysis, writing and editing of  
25  
26  
27 manuscript; ACRV, RI, JFG, INA, BJSB and CNCL: Acquisition, analysis, or interpretation  
28  
29  
30 of data; CNCL, RI, IMVCV: Drafting of the manuscript; ACRV, RI, JFG and IMVCV: Critical  
31  
32  
33 revision of the manuscript for important intellectual content; SSL: Statistical analysis; ACRV:  
34  
35  
36 Obtained funding; VOF and EPSR: technical and material support.  
37  
38  
39  
40  
41  
42  
43

44 **Funding** This study was supported by the National Council for Scientific and  
45  
46  
47 Technological Development (CNPq Project; MCTIC/CNPq/FNDCT/MS/SCTIE/DECIT n.  
48  
49  
50 401235/2020-3); Coordination for the Improvement of Higher Education Personnel  
51  
52  
53 (CAPES: 88887.612787/2021-00); and Federal University of Pará (UFPA-  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 PROPESP/PAPQ-2021). CNPq Research Grants were received by ACRV (#-  
4  
5  
6  
7 301869/2017-0), RI (#312979/2018-5).  
8  
9  
10  
11  
12  
13

14 **Competing interests** None declared  
15  
16  
17  
18  
19  
20

21 **Patient and public involvement** Neither patients, parents nor the public were involved in  
22  
23  
24 the design, conduct or reporting of this research.  
25  
26  
27  
28  
29  
30

31 **Patient consent for publication** Not requirable  
32  
33  
34  
35  
36  
37

38 **Ethics approval** The study was approved by the leaders of the communities and by the  
39  
40  
41 National Research Ethics Committee (*Comissão Nacional de Ética em Pesquisa –*  
42  
43  
44  
45 CONEP; CAAE: 33470020.0.1001.0018), in accordance with the Declarations of  
46  
47  
48 Helsinki.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7 **Data availability statement** Data are available upon reasonable request

8  
9 ([vallinoto@ufpa.br](mailto:vallinoto@ufpa.br))  
10  
11  
12  
13  
14  
15

## 16 REFERENCES

- 17  
18  
19  
20 1. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory  
21 disease in China. *Nature* 2020;579(7798):265-269.  
22  
23  
24  
25  
26  
27 <https://doi.org/10.1038/s41586-020-2008-3>.  
28  
29  
30 2. World Health Organization. Coronavirus disease (COVID-2019) situation reports;  
31  
32  
33  
34 2020. [https://www.who.int/emergencies/diseases/novel-coronavirus-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/)  
35  
36  
37 [2019/situation-reports/](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/) Accessed March 27, 2020.  
38  
39  
40 3. Fiocruz. 4º relatório sobre risco de espalhamento da COVID-19 em populações  
41  
42  
43  
44 indígenas. Risco de espalhamento da COVID-19 em populações indígenas:  
45  
46  
47  
48 considerações preliminares sobre vulnerabilidade geográfica e  
49  
50  
51 sociodemográfica. Available from: <https://portal.fiocruz.br/documento/4o-relatorio->  
52  
53  
54  
55  
56  
57  
58  
59  
60

[sobre-risco-de-espalhamento-da-covid-19-em-populacoes-indigenas](#). Accessed

June 27, 2020.


4. Amigo I. Indigenous communities in Brazil fear pandemic's impact. *Science*. 2020; 368(6489):352. <https://doi.org/10.1126/science.368.6489.352>.
5. Vallinoto ACR, da Silva Torres MK, Vallinoto MC, Cayres-Vallinoto, IMV. The challenges of COVID-19 in the Brazilian Amazonian communities and the importance of seroepidemiological surveillance studies. *Int J Equity Health* 2020;19(1):140. <https://doi.org/10.1186/s12939-020-01256-7>
6. Ramírez JD, Sordillo EM, Gotuzzo E, et al. SARS-CoV-2 in the Amazon region: A harbinger of doom for Amerindians. *PLoS Negl Trop Dis*. 2020;14(10):e0008686. <https://doi.org/10.1371/journal.pntd.0008686>.
7. Rodrigues EPS, Abreu IN, Lima CNC, et al. High prevalence of anti-SARS-CoV-2 IgG antibody in the Xikrin of Bacajá (Kayapó) indigenous population in the Brazilian Amazon. *Int J Equity Health*. 2021;20(1):50. <https://doi.org/10.1186/s12939-021-01392-8>.

- 1  
2  
3  
4 8. Dent R, Santos RV. An Unusual and Fast Disappearing Opportunity: Infectious  
5  
6  
7 Disease, Indigenous Populations, and New Biomedical Knowledge in Amazonia,  
8  
9  
10 1960-1970. *Perspect Sci*. 2017;25(5):585-605.  
11  
12  
13  
14 [https://doi.org/10.1162/POSC\\_a\\_00255](https://doi.org/10.1162/POSC_a_00255).  
15  
16  
17 9. Ishak R, Harrington WJ Jr, Azevedo VN, et al. Identification of human T cell  
18  
19  
20 lymphotropic virus type IIa infection in the Kayapo, an indigenous population of  
21  
22  
23 Brazil. *AIDS Res Hum Retroviruses*. 1995;11(7):813-21.  
24  
25  
26  
27  
28 <https://doi.org/10.1089/aid.1995.11.813>.  
29  
30  
31 10. SESAI – Secretaria Especial de Saúde Indígena. Boletim epidemiológico SESAI  
32  
33  
34 – COVID-19. <http://www.saudeindigena.net.br/coronavirus/mapaEp.php>.  
35  
36  
37  
38 Accessed April 12, 2021).  
39  
40  
41 11. Omer SB, Yildirim I, Forman HP. Herd Immunity and implications for SARS-  
42  
43  
44  
45 CoV-2 control. *JAMA* 2020. <https://doi.org/10.1001/jama.2020.20892>.  
46  
47  
48  
49 12. Buss LF, Prete CA Jr, Abraham CMM, et al. Three-quarters attack rate of SARS-  
50  
51  
52  
53 CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. *Science*  
54  
55  
56 2020;8:eabe9728. <https://doi.org/10.1126/science.abe9728>.  
57  
58  
59  
60

- 1  
2  
3  
4 13. Hallal PC, Hartwig FP, Horta BL, et al. SARS-CoV-2 antibody prevalence in  
5  
6  
7 Brazil: results from two successive nationwide serological household surveys.  
8  
9  
10 *Lancet Glob Health*. 2020;8(11):e1390-e1398. <https://doi.org/10.1016/S2214->  
11  
12  
13  
14 109X(20)30387-9.  
15  
16  
17 14. Crosby AW. Virgin soil epidemics as a factor in the aboriginal depopulation in  
18  
19  
20 America. *William Mary Q*. 1976;33:289-99. PMID: 11633588.  
21  
22  
23  
24 15. Walker RS, Sattenspiel L, Hill KR. Mortality from contact-related epidemics  
25  
26  
27 among indigenous populations in Greater Amazonia. *Sci Rep*. 2015;5:14032.  
28  
29  
30  
31 <https://doi.org/10.1038/srep14032>.  
32  
33  
34  
35  
36  
37

38 Figure 1. Legend.  
39  
40

41  
42 **Figure 1.** Map showing the geographical location of the indigenous communities  
43  
44  
45 investigated enrolled in the present study.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



296x209mm (300 x 300 DPI)



# BMJ Open

## Prevalence of SARS-CoV-2 infection among the Brazilian Amazon indigenous populations

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054271.R1
Article Type:	Original research
Date Submitted by the Author:	13-Oct-2021
Complete List of Authors:	Lima, Carlos Neandro ; Universidade Federal do Para Abreu, Isabella; Universidade Federal do Pará Rodrigues, Eliene Putira; Universidade Federal do Para Freitas, Vanessa; Universidade Federal do Pará Botelho, Bruno José ; Universidade Federal do Para Souza, Sandra; Universidade Federal do Para Cayres-Vallinoto, Izaura; Universidade Federal do Para Guerreiro, João; Universidade Federal do Para Ishak, Ricardo; Universidade Federal do Para Vallinoto, Antonio; Universidade Federal do Para
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Global health, Infectious diseases, Immunology (including allergy), Public health
Keywords:	COVID-19, EPIDEMIOLOGY, INFECTIOUS DISEASES

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Prevalence of SARS-CoV-2 infection among the Brazilian Amazon indigenous**  
4  
5  
6  
7 **populations**  
8  
9  
10  
11  
12  
13

14 Carlos Neandro Cordeiro Lima,<sup>1</sup> Isabella Nogueira Abreu,<sup>1</sup> Eliene Putira Sacuena

15  
16  
17 Rodrigues,<sup>2</sup> Vanessa de Oliveira Freitas,<sup>1</sup> Bruno José Sarmiento Botelho,<sup>1</sup> Sandra

18  
19  
20 Souza Lima,<sup>1</sup> Izaura Maria Vieira Cayres Vallinoto,<sup>1</sup> João Farias Guerreiro,<sup>\* 2</sup> Ricardo

21  
22  
23  
24 Ishak,<sup>\*1</sup> Antonio Carlos Rosário Vallinoto<sup>\*1</sup>  
25  
26  
27  
28  
29  
30

31 <sup>1</sup> Laboratório de Virologia, Instituto de Ciências Biológicas da Universidade Federal do  
32  
33  
34 Pará, Belém, PA, Brasil;

35  
36  
37  
38 <sup>2</sup> Laboratório de Genética Humana e Médica, Instituto de Ciências Biológicas da  
39  
40  
41  
42 Universidade Federal do Pará, Belém, PA, Brasil.  
43  
44  
45  
46  
47  
48

49 \* RI, JFG and ACRV are senior authors of the manuscript  
50  
51  
52  
53  
54  
55

56 **Correspondence to Dr. Antonio Carlos Rosário Vallinoto; [vallinoto@ufpa.br](mailto:vallinoto@ufpa.br)**  
57  
58  
59  
60

## ABSTRACT

**Objectives** The emergence of SARS-CoV-2 and its spread at a pandemic level generated a serious warning over the impact of the infection on vulnerable indigenous populations of the Brazilian Amazon. Thus, the present study aimed to perform seroepidemiological survey for antibodies anti-SARS-CoV-2 in those populations.

**Methods** We performed a cross-sectional study to investigate the prevalence of anti-spike (S1) IgG antibodies among six indigenous ethnic groups living in the State of Pará (Northern Brazil). The villages of Xikrin do Bacajá, Assurini, Araweté, Parakanã, Munduruku and Kararaô were visited from October 2020 to January 2021 and 1,185 individuals, of both sexes, were enrolled in the investigation. Sera were tested for the presence of anti-SARS-CoV-2 IgM and IgG antibodies using two assays (a lateral flow rapid test and an ELISA assay).

**Results** The prevalence of IgM and IgG antibodies was 6.9% and 68,1%, respectively, ranging from 0 to 79.6% with significant differences between ages in two communities

1  
2  
3  
4 (Araweté, Xikrin and Munduruku) and a virulence rate of 0.86%. Herd immunity was  
5  
6  
7 probably attained but the presence of IgM positivity suggests ongoing cases.  
8  
9

10 **Conclusion** SARS-CoV-2 was rapidly spread among the indigenous populations  
11  
12 investigated, but it carried a low mortality. It is necessary to expand the serological  
13  
14 investigations towards other communities in the Amazon region of Brazil.  
15  
16  
17  
18  
19  
20  
21  
22  
23

24 **Keywords:** SARS-CoV-2, COVID-19, Indigenous peoples, Amazon.  
25  
26  
27  
28  
29  
30

### 31 **Strengths and limitations of this study**

32  
33

- 34 • Our previous reports called the attention to the distinct cultural and health  
35 aspects of the Amazonian peoples, the impact of the virus among native peoples,  
36  
37 and the importance of performing seroepidemiological surveys among vulnerable  
38  
39 populations.  
40  
41  
42  
43  
44  
45  
46  
47
- 48 • The results showed that SARS-CoV-2 infection reached the different indigenous  
49  
50 peoples living in the Brazilian Amazon region in an almost homogeneous way.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- The results highlight that SARS-CoV-2 infection hit the indigenous populations as rapidly as the virus entered the Amazon region, without the predicted mortality.
- The high IgG prevalence suggest the herd immunity was probably attained but the presence of IgM positivity showed ongoing cases.
- Furthermore, seroepidemiological surveys are of paramount importance for monitoring the outcome of the national contingency plan for the prevention and control of the epidemic.

## INTRODUCTION

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the first cases of Coronavirus Diseases 2019 (COVID-19) were reported by November 2019, in Wuhan, China.<sup>1</sup> The rapid spread of the virus determined its classification as pandemic by WHO<sup>2</sup> and because of the high morbimortality it highlighted the burden to vulnerable populations, including native indigenous peoples living in the Brazilian Amazonian who are susceptible to the virus and could be devastated by their immunological frailty.<sup>3-6</sup>

1  
2  
3  
4 Three previous reports from our laboratory calls the attention to the distinct cultural  
5  
6  
7 (sharing households), health aspects (coinfections and malnutrition) and the modulation  
8  
9  
10 of infection among these Amazonian peoples, the impact of the virus among native  
11  
12  
13  
14 peoples, and the importance of performing serosurveys among these groups to  
15  
16  
17 determine the spectrum of the illness among them.<sup>5 7 8</sup>  
18  
19

20  
21 Considering the vulnerability of indigenous peoples that inhabit the Brazilian Amazon  
22  
23  
24 region, their supposed inability to respond immunologically to new pathogens that  
25  
26  
27 emerge in the community and, assuming the possible negative impact that the Covid-19  
28  
29  
30 pandemic may have on these communities, the present study aimed to carry out a  
31  
32  
33  
34 seroepidemiological investigation in indigenous populations located in the State of Pará,  
35  
36  
37 through the screening of anti-SARS-CoV-2 antibodies.  
38  
39  
40  
41  
42  
43  
44

## 45 **METHODS**

46  
47  
48 In 2020, a large cross-sectional seroepidemiological surveillance among indigenous  
49  
50  
51 ethnic groups within Para State (Northern Brazil, Amazon), started to investigate the  
52  
53  
54 prevalence of anti-SARS-CoV-2 IgM and IgG antibodies and the impact of the virus on  
55  
56  
57  
58  
59  
60

1  
2  
3 the health of communities. The study was approved by the leaders of the communities  
4  
5  
6  
7 and by the National Research Ethics Committee (*Comissão Nacional de Ética em*  
8  
9  
10 *Pesquisa* – CONEP; CAAE: 33470020.0.1001.0018), in accordance with the  
11  
12  
13  
14 Declarations of Helsinki.

15  
16  
17 From October 2020 to January 2021, multiprofessional health care expeditions were  
18  
19  
20 prepared, composed by our team, the staff of the Health Department of the State of  
21  
22  
23 Para (*Secretaria de Saúde do Estado do Pará – SESPA*) and the Special Indigenous  
24  
25  
26 Health Districts of Altamira and Santarém (*Distrito Sanitário Especial Indígena – DSEI*)  
27  
28 of the Special Secretariat of Indigenous Health (*Secretaria Especial de Saúde Indígena*  
29  
30  
31 – *SESAI-MS*). Six ethnic groups were visited while presenting active cases of COVID-  
32  
33  
34  
35  
36  
37  
38 19, before starting the vaccination campaign among indigenous communities. The  
39  
40  
41 indigenous people underwent a standard clinical examination that could be performed  
42  
43  
44 under field conditions, consisting of anamnesis and physical examination (inspection,  
45  
46  
47  
48 palpation, percussion and auscultation), with assessment of anthropometric data, blood  
49  
50  
51 pressure, body temperature and digital oximetry, in addition to laboratory support for  
52  
53  
54  
55  
56 blood count and biochemical, microbiological and parasitological exams.  
57  
58  
59  
60



1  
2  
3  
4 Access to the indigenous peoples of the basin of the middle Xingu River (Asurini,  
5  
6  
7 Araweté and Parakanã), Iriri River (Kararaô) and Tapajós River (Munduruku) is almost  
8  
9  
10 exclusively fluvial, while access to the Xikrin people, located in the Bacajá River  
11  
12  
13 channel, is currently preferably done by road (Figure 1). The indigenous people studied  
14  
15  
16  
17 were:

18  
19  
20  
21 (i) Araweté, a Tupi-Guarani-speaking people, population of 589 inhabitants, currently  
22  
23  
24 distributed in 22 villages with populations from 7 to 71, located on the banks of the  
25  
26  
27 Xingú River and the Ipixuna stream, right bank tributary of the middle Xingu River, in the  
28  
29  
30 municipality of Altamira (PA). A total of 508 people from all villages were sampled (-  
31  
32  
33  
34  
35 4,8853, -52,4281);

36  
37  
38 (ii) Asurini do Xingu, from the Tupi-Guarani family, totaling 260 individuals distributed in  
39  
40  
41  
42 five villages on the banks of the middle Xingu River (-4,2449, -52,2380); eight people  
43  
44  
45 from Kwatinemu village (n = 139) were studied;

46  
47  
48 (iii) Parakanã, a Tupi-Guarani indigenous people who live in the Apyterewa land, in the  
49  
50  
51  
52 municipalities of Altamira and São Félix do Xingu, in the Xingu basin, Pará, with a  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 population of 782 people living in 16 small villages with population ranging from 17 to  
5  
6  
7 94, of which 210 people were studied (-5,6904, -52,0037);  
8  
9

10 (iv) Xikrin do Bacajá, people of the Kayapó (or Mebengokré) language, Jê linguistic  
11  
12 family, who live in 19 small villages (populations from 11 to 141; current population of  
13  
14 1,051 inhabitants, 3.7160, -53.0546) in the middle Bacajá basin, municipalities of  
15  
16  
17  
18 Senador José Porfírio and Anapú, PA; One hundred individuals from seven villages  
19  
20  
21 were sampled: Kenkrô (39/61), Bakajá (23/109), Mrotdjam (1/128), Pykatum (4/59),  
22  
23  
24  
25 Rapkô (7/60), Pytatko (1941) and Moinorô (13/77);  
26  
27  
28  
29  
30

31 (v) Kararaô, another Jê-speaking Kayapó subgroup, living in four small villages  
32  
33  
34 (Kararaô, n = 15; Kruakrô, n = 15; Pidjôdjã, n = 42 and Rikrekô, n = 11), located in the  
35  
36  
37 lower Iriri river and in the middle Xingu river, in Altamira (PA). A sample of 44 individuals  
38  
39  
40  
41 was collected from a total population of 83 (-3,9112, -52,8044);  
42  
43  
44

45 (vi) Munduruku, an indigenous people belonging to the Munduruku linguistic family, from  
46  
47  
48 the Tupi trunk, lives in the southwest of Pará, in the Tapajós river channel and  
49  
50  
51  
52 tributaries, in the municipalities of Santarém, Itaituba and Jacareacanga. Population of  
53  
54  
55  
56 10,629 distributed in 133 villages. A total of 317 individuals were sampled, 213 from the  
57  
58  
59  
60

1  
2  
3 Nova Karapanatuba village (213/414) and the others from smaller villages around Nova  
4  
5  
6  
7 Karapanatuba, in Jacareacanga. (-3.9112, -52.8044).  
8  
9

10 A blood sample (5 mL) was drawn to test for the presence of anti-SARS-CoV-2 IgM and  
11  
12  
13 IgG antibodies. The prevalence of anti-SARS-CoV-2 IgG and IgM antibodies used a  
14  
15  
16  
17 rapid test (lateral flow method; Guangzhou Wondfo Biotech Co., China) and an enzyme-  
18  
19  
20  
21 linked immunosorbent assay (ELISA; Anti-SARS-CoV-2 S1 IgG, Euroimmun, Brazil),  
22  
23  
24 according to the manufacturer's recommendation. The Kappa test was used to assess  
25  
26  
27  
28 the agreement between the rapid test results and enzyme-linked immunosorbent assay.  
29  
30  
31 The G and chi-square tests were applied to assess the difference in the prevalence of  
32  
33  
34  
35 IgG, among the villages, in relation to sex and age.  
36  
37

38 We estimated the virulence rate considering the case of death to each village over the  
39  
40  
41  
42 number of individuals that were infected with SARS-CoV-2, according to the  
43  
44  
45 seropositivity to IgG.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

## 56 Patient and public involvement

57  
58  
59  
60

1  
2  
3 Neither patients, parents nor the public were involved in the design, conduct or reporting  
4  
5  
6  
7 of this research.  
8  
9  
10  
11  
12  
13

## 14 RESULTS

15  
16  
17 A total of 1,187 subjects was investigated, being 552 males (46.5%) and 635 females  
18  
19  
20 (53.5%). The age ranged from 1 to 95 years old (mean of 26.2, standard deviation of  
21  
22  
23  
24 19.9).  
25  
26  
27

28 Anti-SARS-CoV-2 IgG was detected among 505 (68.1%) individuals by the rapid test  
29  
30  
31 and 815 (68.7%) when tested by the ELISA (Table 1). Eight Asurini did not show  
32  
33  
34 antibodies, but among the other villages, it ranged (by the Elisa test) from 51.7%  
35  
36  
37 (Munduruku) to 79.5% (Araweté and Kararaô). The overall IgG prevalence obtained by  
38  
39  
40  
41 the rapid test and ELISA were similar and the agreement of the results between both  
42  
43  
44 tests, as compared, was 80% - classified as good ( $\kappa=0.4987$ ;  $p<0.001$ ; sensitivity  
45  
46  
47 of 82.1% and specificity of 71.6%). It was observed 33 (2.8%) individuals with  
48  
49  
50  
51 indeterminate result to anti-SARS-CoV-2 IgG antibodies in ELISA test. Additionally, it is  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 worth mentioning that IgM antibodies was detected among 51 (6.9%) individuals from  
5  
6  
7 three villages.  
8  
9

10 There was no statistical significance of IgG prevalence values according to sex (Overall:

11  
12  
13  
14  $\chi^2=0.001$ ,  $p=0.9793$ ; Xikrin:  $\chi^2=0.056$ ,  $p=0.8129$ ; Araweté:  $\chi^2=0.003$ ,  $p=0.9554$ ;

15  
16  
17 Parakanã:  $\chi^2=1.022$ ,  $p=0.3121$ ; Munduruku:  $\chi^2=1.496$ ,  $p=0.2213$ ; Kararaô:  $\chi^2=0.0278$ ,

18  
19  
20  
21  $p=0.0642$ ); but in the Araweté and Xikrin the frequencies were significantly lower among

22  
23  
24 those >31 years old ( $p=0.0065$  and  $p=0.0198$ ) and in the Munduruku a lower frequency

25  
26  
27 among those <6 years old and greater ( $p<0.0001$ ) among those older than 31 years old

28  
29  
30  
31 (Table 2).  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1.** Prevalence of anti-SARS-CoV-2 (S1) IgG antibodies among Indigenous villages

Population	Age range	Sex		Rapid Test results			ELISA IgG anti-Spike S1 results			N Deaths		
		Male N (%)	Female N (%)	N tested	Negative N (%)	IgM N (%)	IgG N (%)	N tested	Negative N (%)		Ind N (%)	IgG N (%)
Xikrin do Bacajá <sup>[7]</sup>	02 a 84	51 (51.0)	49 (49.0)	100	42 (42)	nt	58 (58)	100	27 (27)	0 (0)	73 (73)	01
Asurini	17 a 42	0 (0)	8 (100)	0	nt	nt	nt	08	7 (87.5)	1 (12.5)	0 (0)	0
Araweté	8m a 84	258 (50.8)	250 (49.2)	236	29 (12.3)	11 (4.7)	196 (83)	508	92 (18.1)	12 (2.4)	404 (79.5)	0
Parakanã	7m to 95 y	106 (50.5)	104 (49.5)	195	06 (3.1)	39 (20)	150 (76.9)	210	65 (30.9)	06 (2.8)	139 (66.2)	01
Munduruku	7 m to 89 y	116 (36.6)	201 (63.4)	166	96 (57.8)	nt	70 (42.2)	317	139 (43.9)	14 (4.4)	164 (51.7)	05
Kararaô	1 a 94	21 (47.7)	23 (52.3)	44	13 (29.5)	1 (2.3)	30 (68.2)	44	9 (20.4)	0 (0)	35 (79.5)	0
Total	7m a 95 y	552 (46.5)	635 (53.5)	741	185 (25.0)	51 (6.9)	505 (68.1)	1.187	339 (28.5)	33 (2.8)	815 (68.7)	07

M (months); Y (years), nt (not tested); [7] Rodrigues et al. (2021); Ind: Indeterminate

**Table 2.** Age and sex distribution to anti-SARS-CoV-2 (S1) IgG antibodies among Indigenous villages

Age	Xikrin <sup>[7]</sup>		Asurini		Araweté		Parakanã		Munduruku		Kararaô		Total n/ total (%)
	male	female	male	female	male	female	male	female	male	female	male	female	
0-6	5	2	0	0	44	27	10	6	6	5	3	1	109/1,187 (9.2)
>6 a 16	15	11	0	0	61	56	18	18	8	17	6	8	218/1,187 (18.4)
>16 a 31	9	13	0	0	56	66	12	21	14	44	2	6	243/1,187 (20.5)
>31	10	8	0	0	45	49	27	27	26	42	3	6	243/1,187 (20.5)
*not informed	0	0	0	0	0	0	0	0	1	1	0	0	2/1,187 (0.2)
Total	39	34	0	0	206	198	67	72	55	109	14	21	815/1,187 (68.7)

[7] Rodrigues et al. (2021); Age distribution: (Overall:  $\chi^2=8.2$ ;  $p=0.042$ ); (Xikrin:  $G=8.15$ ;  $p=0.0198$ ); (Araweté:  $\chi^2=12.3$ ;  $p=0.0065$ ); (Parakanã:  $\chi^2=3.9$ ;  $p=0.2753$ ); (Munduruku:  $\chi^2=23.8$ ;  $p<0.0001$ ); (Kararaô:  $G=4.4$ ;  $p=0.2213$ ). G - G test;  $\chi^2$  - Qui-square.

1  
2  
3  
4  
5  
6  
7 The main clinical manifestations reported among infected individuals were coughing,  
8  
9  
10 dyspnea, coryza, fever, fatigue, diarrhea, ear pain, headache, chest and back pain.  
11  
12

13  
14 There were seven deaths among the 815 infected persons showing a virulence rate of  
15  
16  
17 0.86%.  
18  
19  
20  
21  
22  
23

## 24 DISCUSSION

25  
26  
27  
28 The high prevalence of IgG anti-SARS-CoV-2 antibodies reported herein show that the  
29  
30  
31 new coronavirus infection reached indigenous populations in a wide way. Introduction of  
32  
33  
34 new infectious agents among vulnerable indigenous peoples is thought to be a heavy  
35  
36  
37 burden because of the low genetic variability among genes that control the immune  
38  
39  
40 response,<sup>9</sup> an important element working as a selective pressure over indigenous  
41  
42  
43 peoples since the initial colonization process of the Amazon region of Brazil.  
44  
45  
46

47  
48  
49 SARS-CoV-2 brought the question again as to how the virus would affect native  
50  
51  
52 peoples? Despite the theoretical arguments for the possible speculative devastation of  
53  
54  
55 indigenous groups,<sup>6</sup> there was no confirmed evidence of susceptibility to Covid-19 in the  
56  
57  
58  
59  
60



1  
2  
3 presence of coinfections and pre-existing conditions, including obesity and malnutrition  
4  
5  
6  
7 as previously suggested.<sup>4 5</sup>  
8  
9

10 Most of the indigenous peoples of the Amazon region of Brazil, including those of the  
11  
12  
13  
14 present study, present endemic diseases as malaria, tuberculosis, virus hepatitis and, to  
15  
16  
17 HTLV-2 hyperendemic infections among Xikrin, Kararaô, Munduruku and Parakanã.<sup>10</sup>  
18  
19

20  
21 Presently, there is no scientific evidence for host modulation of SARS-CoV-2 in the  
22  
23  
24 presence of these coinfections, but researches in order to investigate these coinfections  
25  
26  
27 are of paramount importance for a better understanding of the outcome of SARS-CoV-2  
28  
29  
30  
31 infection. Furthermore, environmental and social conditions are important factors that  
32  
33  
34 could impact on COVID-19 among indigenous communities,<sup>3 4</sup> including the lack of  
35  
36  
37  
38 drinking water and malnutrition, which might had been potentialized after the  
39  
40  
41  
42 prophylactic isolation measures.  
43  
44

45 In our previous report the quality of tests to measure the presence of antibodies was  
46  
47  
48 raised.<sup>7</sup> It is important that antibodies to SARS-CoV-2 are detected using tests with  
49  
50  
51  
52 greater sensitivity and specificity to obtain accurate prevalence rates. Rapid tests  
53  
54  
55  
56 usually show low sensitivity and yield false negative results and false-positive results  
57  
58  
59

1  
2  
3 due to cross-reactions. In the present study, two methodologies were used and the  
4  
5  
6  
7 agreement of the results of the rapid test in relation to ELISA was good and the IgG  
8  
9  
10 prevalence values similar.

11  
12  
13  
14 In contrast to the genetic and socio-environmental vulnerability the results showed  
15  
16  
17 SARS-CoV-2 infection evenly distributed, with a high prevalence of the virus and few  
18  
19  
20 reported deaths, confirming the official results by Special Secretariat of Indigenous  
21  
22  
23 Health (SESAI) in its COVID-19 epidemiological bulletin.<sup>11</sup>

24  
25  
26  
27  
28 The prevalence of anti-SARS-CoV-2 IgG antibodies shows a high dissemination of the  
29  
30  
31 virus spread favored by inherent social and cultural difficulties of keeping social  
32  
33  
34 distance, sharing households with other families and wearing masks correctly. In spite  
35  
36  
37 of the high prevalence of infection, during the investigation they were still facing the  
38  
39  
40 epidemic, showed by the detection of IgM antibodies in three villages. It is relevant to  
41  
42  
43 mention that three villages are more than 100Km apart from each other and there is no  
44  
45  
46 simple way of communication among them. This raises another important question in  
47  
48  
49 regard to herd protective immunity. Apparently, the communities achieved herd  
50  
51  
52 immunity levels, when reaching at least 60% seropositivity for IgG,<sup>12</sup> similarly as found  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 in Manaus, the capital of the Amazonas State.<sup>13</sup> However, differently from what is seen  
5  
6  
7 among urban areas,<sup>14</sup> virgin soil epidemics generally exhaust susceptible individuals  
8  
9  
10 before it comes to an end,<sup>15</sup> and the present epidemic is still not totally explained and  
11  
12  
13 understood. The high seroprevalence of IgG anti-SARS-CoV-2 antibodies reported  
14  
15  
16 herein among vulnerable Amazon Indigenous peoples, is comparable to our recent  
17  
18  
19 finding among Venezuelan indigenous Warao refugees residing in Belem city, the  
20  
21  
22 capital of Para State, where the infection was detected among 83% of the subjects  
23  
24  
25  
26  
27  
28 living in conditions of vulnerability.<sup>16</sup> Similar results were reported among indigenous  
29  
30  
31 people living in the surrounding area of Manaus, where the number of individuals  
32  
33  
34  
35 sharing households was a risk for virus infection.<sup>17</sup>

36  
37  
38 The results show new information over the SARS-CoV-2 epidemic among indigenous  
39  
40  
41 peoples and provides the Brazilian government with information to establish adequate  
42  
43  
44  
45 measures to control the epidemic among Brazilian indigenous communities in the  
46  
47  
48 Amazon region.

## 55 56 CONCLUSION

1  
2  
3 SARS-CoV-2 infection reached the indigenous populations from the State of Para as  
4  
5  
6  
7 rapid as the virus entered the Amazon region, confirming our previous alert to the need  
8  
9  
10 of serological studies for surveillance, minimizing the burden of the epidemic and to  
11  
12  
13  
14 promote indigenous health policies.<sup>5</sup>  
15

16  
17 In spite of the suggestion of high mortality and chaos facing the Amerindian  
18  
19  
20 populations,<sup>6</sup> the majority of the cases was asymptomatic or mild, with low fatality rate,  
21  
22  
23  
24 supporting analysis that shows that the mortality associated with epidemics following  
25  
26  
27 contact of Amazonian indigenous communities with urban communities has decreased  
28  
29  
30  
31 in recent years.<sup>18</sup>  
32  
33

34  
35 Finally, continuing seroepidemiological surveys are of paramount importance for  
36  
37  
38 monitoring the outcome of the national contingency plan for the prevention and control  
39  
40  
41  
42 of the epidemic, by a mass vaccination program for indigenous peoples started by  
43  
44  
45 February 2021.  
46  
47  
48  
49  
50  
51

52 **Acknowledgments** We thank the Indigenous populations for authorizing the study and  
53  
54  
55  
56 the institutions that provided technical support for the development and implementation  
57  
58  
59  
60

1  
2  
3 of this study. Our especial gratitude to Vilson Monteiro and Hailton Monteiro for  
4  
5  
6  
7 laboratorial assistance during the expeditions to Indigenous villages.  
8  
9

10  
11  
12  
13  
14 **Contributor** ACRV, JFG and RI: conception of idea, data analysis, writing and editing of  
15  
16 manuscript; ACRV, RI, JFG, INA, BJSB and CNCL: Acquisition, analysis, or  
17  
18 interpretation of data; CNCL, RI, IMVCV: Drafting of the manuscript; ACRV, RI, JFG  
19  
20 and IMVCV: Critical revision of the manuscript for important intellectual content; SSL:  
21  
22 Statistical analysis; ACRV: Obtained funding; VOF and EPSR: technical and material  
23  
24 support.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 **Funding** This study was supported by the National Council for Scientific and  
39  
40 Technological Development (CNPq Project; MCTIC/CNPq/FNDCT/MS/SCTIE/DECIT n.  
41  
42 401235/2020-3); Coordination for the Improvement of Higher Education Personnel  
43  
44 (CAPES: 88887.612787/2021-00); and Federal University of Pará (UFPA-  
45  
46 PROPESP/PAPQ-2021). CNPq Research Grants were received by ACRV (#-  
47  
48 301869/2017-0), RI (#312979/2018-5).  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7 **Competing interests** None declared  
8  
9

10  
11  
12  
13  
14 **Patient and public involvement** Neither patients, parents nor the public were involved in  
15  
16  
17 the design, conduct or reporting of this research.  
18  
19

20  
21  
22  
23  
24 **Patient consent for publication** Not requirable  
25  
26  
27

28  
29  
30  
31 **Ethics approval** The study was approved by the leaders of the communities and by the  
32  
33  
34 National Research Ethics Committee (*Comissão Nacional de Ética em Pesquisa –*  
35  
36  
37  
38 CONEP; CAAE: 33470020.0.1001.0018), in accordance with the Declarations of  
39  
40  
41 Helsinki.  
42  
43  
44  
45  
46  
47

48  
49 **Data availability statement** Data are available upon reasonable request  
50  
51 ([vallinoto@ufpa.br](mailto:vallinoto@ufpa.br))  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  

## REFERENCES

1. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. *Nature* 2020;579(7798):265-269.  
<https://doi.org/10.1038/s41586-020-2008-3>.
2. World Health Organization. Coronavirus disease (COVID-2019) situation reports; 2020. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/> Accessed March 27, 2020.
3. Fiocruz. 4º relatório sobre risco de espalhamento da COVID-19 em populações indígenas. Risco de espalhamento da COVID-19 em populações indígenas: considerações preliminares sobre vulnerabilidade geográfica e sociodemográfica. Available from: <https://portal.fiocruz.br/documento/4o-relatorio-sobre-risco-de-espalhamento-da-covid-19-em-populacoes-indigenas>. Accessed June 27, 2020.
4. Amigo I. Indigenous communities in Brazil fear pandemic's impact. *Science*. 2020; 368(6489):352. <https://doi.org/10.1126/science.368.6489.352>.

- 1  
2  
3  
4 5. Vallinoto ACR, da Silva Torres MK, Vallinoto MC, Cayres-Vallinoto, IMV. The  
5  
6  
7 challenges of COVID-19 in the Brazilian Amazonian communities and the  
8  
9  
10 importance of seroepidemiological surveillance studies. *Int J Equity Health*  
11  
12  
13 2020;19(1):140. <https://doi.org/10.1186/s12939-020-01256-7>  
14  
15  
16
- 17 6. Ramírez JD, Sordillo EM, Gotuzzo E, et al. SARS-CoV-2 in the Amazon region:  
18  
19  
20 A harbinger of doom for Amerindians. *PLoS Negl Trop Dis*.  
21  
22  
23 2020;14(10):e0008686. <https://doi.org/10.1371/journal.pntd.0008686>.  
24  
25  
26
- 27 7. Rodrigues EPS, Abreu IN, Lima CNC, et al. High prevalence of anti-SARS-CoV-  
28  
29  
30 2 IgG antibody in the Xikrin of Bacajá (Kayapó) indigenous population in the  
31  
32  
33 brazilian Amazon. *Int J Equity Health*. 2021;20(1):50.  
34  
35  
36  
37 <https://doi.org/10.1186/s12939-021-01392-8>.  
38  
39  
40
- 41 8. Ishak R, Guerreiro JF and Vallinoto ACR. Why Did They Not Die?. *Austin J*  
42  
43  
44  
45 *Public Health Epidemiol*. 2021;8(3):1106.  
46  
47  
48
- 49 9. Dent R, Santos RV. An Unusual and Fast Disappearing Opportunity: Infectious  
50  
51  
52 Disease, Indigenous Populations, and New Biomedical Knowledge in Amazonia,  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 1960-1970. *Perspect Sci*. 2017;25(5):585-605.

5  
6  
7 [https://doi.org/10.1162/POSC\\_a\\_00255](https://doi.org/10.1162/POSC_a_00255).

8  
9  
10 10. Ishak R, Harrington WJ Jr, Azevedo VN, et al. Identification of human T cell

11  
12  
13  
14 lymphotropic virus type IIa infection in the Kayapo, an indigenous population of

15  
16  
17 Brazil. *AIDS Res Hum Retroviruses*. 1995;11(7):813-21.

18  
19  
20  
21 <https://doi.org/10.1089/aid.1995.11.813>.

22  
23  
24 11. SESAI – Secretaria Especial de Saúde Indígena. Boletim epidemiológico SESAI

25  
26  
27 – COVID-19. <http://www.saudeindigena.net.br/coronavirus/mapaEp.php>.

28  
29  
30  
31 Accessed April 12, 2021).

32  
33  
34 12. Omer SB, Yildirim I, Forman HP. Herd Immunity and implications for SARS-

35  
36  
37  
38 CoV-2 control. *JAMA* 2020. <https://doi.org/10.1001/jama.2020.20892>.

39  
40  
41 13. Buss LF, Prete CA Jr, Abraham CMM, et al. Three-quarters attack rate of SARS-

42  
43  
44  
45 CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. *Science*

46  
47  
48  
49 2020;8:eabe9728. <https://doi.org/10.1126/science.abe9728>.

50  
51  
52 14. Hallal PC, Hartwig FP, Horta BL, et al. SARS-CoV-2 antibody prevalence in

53  
54  
55  
56 Brazil: results from two successive nationwide serological household surveys.

1  
2  
3  
4 *Lancet Glob Health*. 2020;8(11):e1390-e1398. <https://doi.org/10.1016/S2214->  
5  
6  
7 109X(20)30387-9.  
8  
9

10  
11 15. Crosby AW. Virgin soil epidemics as a factor in the aboriginal depopulation in  
12  
13  
14 America. *William Mary Q*. 1976;33:289-99. PMID: 11633588.  
15

16  
17 16. da Silva HP, Abreu IN, Lima CNC, et al. Migration in times of pandemic: SARS-  
18  
19  
20  
21 CoV-2 infection among the Warao indigenous refugees in Belém, Pará,  
22  
23  
24 Amazonia, Brazil. *BMC Public Health*. 2021;21(1):1659. doi: 10.1186/s12889-  
25  
26  
27 021-11696-7.  
28  
29


30  
31 17. Pontes GS, de Melo Silva J, Pinheiro-Silva R, Barbosa AN, Santos LC, de  
32  
33  
34 Pádua Quirino Ramalho A, de Castro Alves CE, da Silva DF, de Oliveira LC, da  
35  
36  
37  
38 Costa AG, Bruno AC. Increased vulnerability to SARS-CoV-2 infection among  
39  
40  
41  
42 indigenous people living in the urban area of Manaus. *Sci Rep*.  
43  
44  
45 2021;11(1):17534. doi: 10.1038/s41598-021-96843-1.  
46  
47

48  
49 18. Walker RS, Sattenspiel L, Hill KR. Mortality from contact-related epidemics  
50  
51  
52 among indigenous populations in Greater Amazonia. *Sci Rep*. 2015;5:14032.  
53  
54  
55  
56 <https://doi.org/10.1038/srep14032>.  
57  
58

1  
2  
3  
4  
5  
6  
7 Figure Legend.  
8  
9

10 **Figure 1.** Map showing the geographical location of the indigenous communities  
11  
12  
13  
14 investigated enrolled in the present study.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



296x209mm (600 x 600 DPI)

# BMJ Open

## Prevalence of anti-SARS-CoV-2 antibodies among the Brazilian Amazon indigenous populations

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054271.R2
Article Type:	Original research
Date Submitted by the Author:	22-Nov-2021
Complete List of Authors:	Lima, Carlos Neandro ; Universidade Federal do Para Abreu, Isabella; Universidade Federal do Pará Rodrigues, Eliene Putira; Universidade Federal do Para Freitas, Vanessa; Universidade Federal do Pará Botelho, Bruno José ; Universidade Federal do Para Souza, Sandra; Universidade Federal do Para Cayres-Vallinoto, Izaura; Universidade Federal do Para Guerreiro, João; Universidade Federal do Para Ishak, Ricardo; Universidade Federal do Para Vallinoto, Antonio; Universidade Federal do Para
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Global health, Infectious diseases, Immunology (including allergy), Public health
Keywords:	COVID-19, EPIDEMIOLOGY, INFECTIOUS DISEASES

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Prevalence of anti-SARS-CoV-2 antibodies among the Brazilian Amazon indigenous**  
4  
5  
6  
7 **populations**  
8  
9  
10  
11  
12  
13

14 Carlos Neandro Cordeiro Lima,<sup>1</sup> Isabella Nogueira Abreu,<sup>1</sup> Eliene Putira Sacuena

15  
16  
17 Rodrigues,<sup>2</sup> Vanessa de Oliveira Freitas,<sup>1</sup> Bruno José Sarmiento Botelho,<sup>1</sup> Sandra

18  
19  
20 Souza Lima,<sup>1</sup> Izaura Maria Vieira Cayres Vallinoto,<sup>1</sup> João Farias Guerreiro,<sup>\* 2</sup> Ricardo

21  
22  
23  
24 Ishak,<sup>\*1</sup> Antonio Carlos Rosário Vallinoto<sup>\*1</sup>  
25  
26  
27  
28  
29  
30

31  
32 <sup>1</sup> Laboratório de Virologia, Instituto de Ciências Biológicas da Universidade Federal do  
33  
34 Pará, Belém, PA, Brasil;

35  
36  
37  
38 <sup>2</sup> Laboratório de Genética Humana e Médica, Instituto de Ciências Biológicas da  
39  
40  
41  
42 Universidade Federal do Pará, Belém, PA, Brasil.  
43  
44  
45  
46  
47  
48

49 \* RI, JFG and ACRV are senior authors of the manuscript  
50  
51  
52  
53  
54  
55

56 **Correspondence to Dr. Antonio Carlos Rosário Vallinoto; [vallinoto@ufpa.br](mailto:vallinoto@ufpa.br)**  
57  
58  
59  
60

## ABSTRACT

**Objectives** The emergence of SARS-CoV-2 and its spread at a pandemic level generated a serious warning over the impact of the infection on vulnerable indigenous populations of the Brazilian Amazon. Thus, the present study aimed to perform seroepidemiological survey for antibodies anti-SARS-CoV-2 in those populations.

**Design** We performed a cross-sectional study to investigate the prevalence of anti-spike (S1) IgG antibodies.

**Setting** Six indigenous ethnic groups living in the State of Pará (Northern Brazil) were investigated. The villages of Xikrin do Bacajá, Assurini, Araweté, Parakanã, Munduruku and Kararaô were visited from October 2020 to January 2021

**Participants** A total of 1,185 individuals, of both sexes, were enrolled in the investigation.

**Method** Plasma were tested for the presence of anti-SARS-CoV-2 IgM and IgG antibodies using two assays (a lateral flow rapid test and an ELISA assay).



1  
2  
3 **Results** The prevalence of IgM and IgG antibodies was 6.9% and 68,1%, respectively,  
4  
5  
6  
7 ranging from 0 to 79.6% with significant differences ( $p<0.001$ ) between ages in two  
8  
9  
10 communities (Araweté, Xikrin and Munduruku) and a virulence rate of 0.86%. Herd  
11  
12  
13  
14 immunity was probably attained, similarly as found in other communities of Amazon.  
15

16  
17 **Conclusions** SARS-CoV-2 was rapidly spread among the indigenous populations  
18  
19  
20 investigated, but it carried a low mortality. It is necessary to expand the serological  
21  
22  
23  
24 investigations towards other communities in the Amazon region of Brazil.  
25

26  
27  
28  
29  
30  
31 **Keywords:** SARS-CoV-2, COVID-19, Indigenous peoples, Amazon.  
32  
33

### 34 35 36 37 38 **Strengths and limitations of this study** 39

- 40  
41  
42 • Our previous reports called the attention to the distinct cultural and health  
43  
44 aspects of the Amazonian peoples, the impact of the virus among native peoples,  
45  
46 and the importance of performing seroepidemiological surveys among vulnerable  
47  
48  
49  
50  
51  
52 populations.  
53  
54  
55  
56  
57  
58  
59  
60

- The results showed that SARS-CoV-2 infection reached the different indigenous peoples living in the Brazilian Amazon region in an almost homogeneous way.
- The results highlight that SARS-CoV-2 infection hit the indigenous populations as rapidly as the virus entered the Amazon region, without the predicted mortality.
- The high IgG prevalence suggest the herd immunity was probably attained but the presence of IgM positivity showed ongoing cases.
- Furthermore, seroepidemiological surveys are of paramount importance for monitoring the outcome of the national contingency plan for the prevention and control of the epidemic.

## INTRODUCTION

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the first cases of Coronavirus Diseases 2019 (COVID-19) were reported by November 2019, in Wuhan, China.<sup>1</sup> The rapid spread of the virus determined its classification as pandemic by WHO<sup>2</sup> and because of the high morbimortality it highlighted the burden to vulnerable

1  
2  
3 populations, including native indigenous peoples living in the Brazilian Amazonian who  
4  
5  
6  
7 are susceptible to the virus and could be devastated by their immunological frailty.<sup>3-6</sup>  
8  
9

10 Three previous reports from our laboratory calls the attention to the distinct cultural  
11  
12  
13 (sharing households), health aspects (coinfections and malnutrition) and the modulation  
14  
15  
16  
17 of infection among these Amazonian peoples, the impact of the virus among native  
18  
19  
20  
21 peoples, and the importance of performing serosurveys among these groups to  
22  
23  
24 determine the spectrum of the illness among them.<sup>5 7 8</sup>  
25  
26  
27

28 Considering the vulnerability of indigenous peoples that inhabit the Brazilian Amazon  
29  
30  
31 region, their supposed inability to respond immunologically to new pathogens that  
32  
33  
34  
35 emerge in the community and, assuming the possible negative impact that the Covid-19  
36  
37  
38 pandemic may have on these communities, the present study aimed to carry out a  
39  
40  
41  
42 seroepidemiological investigation in indigenous populations located in the State of Pará,  
43  
44  
45 through the screening of anti-SARS-CoV-2 antibodies.  
46  
47  
48  
49  
50  
51

## 52 **METHODS**

### 53 54 55 **Type of study and ethic aspects** 56 57 58 59 60

1  
2  
3  
4 In 2020, a large cross-sectional seroepidemiological surveillance among indigenous  
5  
6  
7 ethnic groups within Para State (Northern Brazil, Amazon), started to investigate the  
8  
9  
10 prevalence of anti-SARS-CoV-2 IgM and IgG antibodies and the impact of the virus on  
11  
12  
13 the health of communities. The study was approved by the leaders of the communities  
14  
15  
16 and by the National Research Ethics Committee (*Comissão Nacional de Ética em*  
17  
18  
19 *Pesquisa* – CONEP; CAAE: 33470020.0.1001.0018), in accordance with the  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Declarations of Helsinki.

### Study population

35 From October 2020 to January 2021, multiprofessional health care expeditions were  
36  
37  
38 prepared, composed by our team, the staff of the Health Department of the State of  
39  
40  
41 Para (*Secretaria de Saúde do Estado do Pará – SESPA*) and the Special Indigenous  
42  
43  
44 Health Districts of Altamira and Santarém (*Distrito Sanitário Especial Indígena – DSEI*)  
45  
46  
47 of the Special Secretariat of Indigenous Health (*Secretaria Especial de Saúde Indígena*  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
– *SESAI-MS*). Six ethnic groups were visited while presenting active cases of COVID-  
19, before starting the vaccination campaign among indigenous communities. The

1  
2  
3 indigenous people underwent a standard clinical examination that could be performed  
4  
5  
6  
7 under field conditions, consisting of anamnesis and physical examination (inspection,  
8  
9  
10 palpation, percussion and auscultation), with assessment of anthropometric data, blood  
11  
12  
13  
14 pressure, body temperature and digital oximetry, in addition to laboratory support for  
15  
16  
17 blood count and biochemical, microbiological and parasitological exams.  
18  
19  
20

21 Access to the indigenous peoples of the basin of the middle Xingu River (Asurini,  
22  
23  
24 Araweté and Parakanã), Iriri River (Kararaô) and Tapajós River (Munduruku) is almost  
25  
26  
27 exclusively fluvial, while access to the Xikrin people, located in the Bacajá River  
28  
29  
30  
31 channel, is currently preferably done by road (Figure 1). The indigenous people studied  
32  
33  
34  
35 were:

36  
37  
38 (i) Araweté, a Tupi-Guarani-speaking people, population of 589 inhabitants, currently  
39  
40  
41 distributed in 22 villages with populations from 7 to 71, located on the banks of the  
42  
43  
44 Xingú River and the Ipixuna stream (-4,8853, -52,4281), right bank tributary of the  
45  
46  
47  
48 middle Xingu River, in the municipality of Altamira (PA). A total of 508 people from all  
49  
50  
51  
52 villages were sampled;  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 (ii) Asurini do Xingu, from the Tupi-Guarani family, totaling 260 individuals distributed in  
5  
6  
7 five villages on the banks of the middle Xingu River (-4,2449, -52,2380); eight people  
8  
9  
10 from Kwatinemu village (n = 139) were studied;

11  
12  
13  
14 (iii) Parakanã, a Tupi-Guarani indigenous people who live in the Apyterewa land, in the  
15  
16  
17 municipalities of Altamira and São Félix do Xingu, in the Xingu basin (-5,6904, -  
18  
19  
20 52,0037), Pará, with a population of 782 people living in 16 small villages with  
21  
22  
23 population ranging from 17 to 94, of which 210 people were studied;

24  
25  
26  
27 (iv) Xikrin do Bacajá, people of the Kayapó (or Mebengokré) language, Jê linguistic  
28  
29  
30 family, who live in 19 small villages (populations from 11 to 141; current population of  
31  
32  
33 1,051 inhabitants, in the middle Bacajá basin (-3.7160, -53.0546), municipalities of  
34  
35  
36 Senador José Porfírio and Anapú, PA; One hundred individuals from seven villages  
37  
38  
39 were sampled: Kenkrô (39/61), Bakajá (23/109), Mrotdjam (1/128), Pykatum (4/59),  
40  
41  
42 Rapkô (7/60), Pytatko (1941) and Moinorô (13/77);  
43  
44  
45  
46

47  
48  
49 (v) Kararaô, another Jê-speaking Kayapó subgroup, living in four small villages  
50  
51  
52 (Kararaô, n = 15; Kruakrô, n = 15; Pidjôdjã, n = 42 and Rikrekô, n = 11), located in the  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 lower Iriri river and in the middle Xingu river (-3,9112, -52,8044), in Altamira (PA). A

4  
5  
6  
7 sample of 44 individuals was collected from a total population of 83;

8  
9  
10 (vi) Munduruku, an indigenous people belonging to the Munduruku linguistic family, from

11  
12  
13 the Tupi trunk, lives in the southwest of Pará, in the Tapajós river channel and

14  
15  
16 tributaries, in the municipalities of Santarém, Itaituba and Jacareacanga (-3.9112, -

17  
18  
19 52.8044). Population of 10,629 distributed in 133 villages. A total of 317 individuals

20  
21  
22 were sampled, 213 from the Nova Karapanatuba village (213/414) and the others from

23  
24  
25 smaller villages around Nova Karapanatuba, in Jacareacanga (PA).

### 26 27 28 29 30 31 32 33 34 **Anti-SARS-CoV-2 antibody assays**

35  
36  
37 A blood sample (5 mL) was drawn and the plasma tested for the presence of anti-

38  
39  
40 SARS-CoV-2 IgM and IgG antibodies. The prevalence of anti-SARS-CoV-2 IgM and IgG

41  
42  
43 antibodies used a rapid test (lateral flow method; Guangzhou Wondfo Biotech Co.,

44  
45  
46 China) and an enzyme-linked immunosorbent assay (ELISA; Anti-SARS-CoV-2 S1 IgG,

47  
48  
49 Euroimmun, Brazil), respectively, according to the manufacturer's recommendation.

### 50 51 52 53 54 55 **Data analysis**

1  
2  
3  
4 The Kappa test was used to assess the agreement between the rapid test results and  
5  
6  
7 enzyme-linked immunosorbent assay. The G and chi-square tests were applied to  
8  
9  
10 assess the difference in the prevalence of IgG, among the villages, in relation to sex  
11  
12  
13  
14 and age.  
15

16  
17 We estimated the virulence rate considering the case of death to each village over the  
18  
19  
20 number of individuals that were infected with SARS-CoV-2, according to the  
21  
22  
23  
24 seropositivity to IgG.  
25  
26  
27  
28  
29  
30

### 31 **Patient and public involvement**

32  
33  
34  
35 Neither patients, parents nor the public were involved in the design, conduct or reporting  
36  
37  
38 of this research.  
39  
40  
41  
42  
43  
44

## 45 **RESULTS**

46  
47  
48 A total of 1,187 subjects was investigated, being 552 males (46.5%) and 635 females  
49  
50  
51  
52 (53.5%). The age ranged from 1 to 95 years old (mean of 26.2, standard deviation of  
53  
54  
55  
56 19.9).  
57  
58  
59  
60



1  
2  
3  
4 Anti-SARS-CoV-2 IgG was detected among 505 (68.1%) individuals by the rapid test  
5  
6  
7 and 815 (68.7%) when tested by the ELISA (Table 1). Eight Asurini did not show  
8  
9  
10 antibodies, but among the other villages, it ranged (by the Elisa test) from 51.7%  
11  
12  
13 (Munduruku) to 79.5% (Araweté and Kararaô). The overall IgG prevalence obtained by  
14  
15  
16 the rapid test and ELISA were similar and the agreement of the results between both  
17  
18  
19 tests, as compared, was 80% - classified as good ( $\kappa=0.4987$ ;  $p<0.001$ ; sensitivity  
20  
21  
22 of 82.1% and specificity of 71.6%). It was observed 33 (2.8%) individuals with  
23  
24  
25 indeterminate result to anti-SARS-CoV-2 IgG antibodies in ELISA test. Additionally, it is  
26  
27  
28 worth mentioning that IgM antibodies was detected among 51 (6.9%) individuals from  
29  
30  
31 three villages.  
32  
33  
34  
35  
36  
37

38 There was no statistical significance of IgG prevalence values according to sex (Overall:  
39  
40  
41  $\chi^2=0.001$ ,  $p=0.9793$ ; Xikrin:  $\chi^2=0.056$ ,  $p=0.8129$ ; Araweté:  $\chi^2=0.003$ ,  $p=0.9554$ ;  
42  
43  
44 Parakanã:  $\chi^2=1.022$ ,  $p=0.3121$ ; Munduruku:  $\chi^2=1.496$ ,  $p=0.2213$ ; Kararaô:  $\chi^2=0.0278$ ,  
45  
46  
47  $p=0.0642$ ). In regarding to the ages, in the Araweté and Xikrin the frequencies were  
48  
49  
50 significantly lower among those >31 years old ( $p=0.0065$  and  $p=0.0198$ ) and in the  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Munduruku a lower frequency among those <6 years old and greater ( $p<0.0001$ ) among those older than 31 years old (Table 2).

For peer review only

**Table 1.** Prevalence of anti-SARS-CoV-2 (S1) IgG antibodies among Indigenous villages

Population	Age range	Sex		Rapid Test results			ELISA IgG anti-Spike S1 results			N Deaths		
		Male N (%)	Female N (%)	N tested	Negative N (%)	IgM N (%)	IgG N (%)	N tested	Negative N (%)		Ind N (%)	IgG N (%)
Xikrin do Bacajá <sup>[7]</sup>	02 a 84	51 (51.0)	49 (49.0)	100	42 (42)	nt	58 (58)	100	27 (27)	0 (0)	73 (73)	01
Asurini	17 a 42	0 (0)	8 (100)	0	nt	nt	nt	08	7 (87.5)	1 (12.5)	0 (0)	0
Araweté	8m a 84	258 (50.8)	250 (49.2)	236	29 (12.3)	11 (4.7)	196 (83)	508	92 (18.1)	12 (2.4)	404 (79.5)	0
Parakanã	7m to 95 y	106 (50.5)	104 (49.5)	195	06 (3.1)	39 (20)	150 (76.9)	210	65 (30.9)	06 (2.8)	139 (66.2)	01
Munduruku	7 m to 89 y	116 (36.6)	201 (63.4)	166	96 (57.8)	nt	70 (42.2)	317	139 (43.9)	14 (4.4)	164 (51.7)	05
Kararaô	1 a 94	21 (47.7)	23 (52.3)	44	13 (29.5)	1 (2.3)	30 (68.2)	44	9 (20.4)	0 (0)	35 (79.5)	0
Total	7m a 95 y	552 (46.5)	635 (53.5)	741	185 (25.0)	51 (6.9)	505 (68.1)	1.187	339 (28.5)	33 (2.8)	815 (68.7)	07

M (months); Y (years), nt (not tested); [7] Rodrigues et al. (2021); Ind: Indeterminate

**Table 2.** Age and sex distribution to anti-SARS-CoV-2 (S1) IgG antibodies among Indigenous villages

Age	Xikrin <sup>[7]</sup>		Asurini		Araweté		Parakanã		Munduruku		Kararaô		Total n/ total (%)
	male	female	male	female	male	female	male	female	male	female	male	female	
0-6	5	2	0	0	44	27	10	6	6	5	3	1	109/1,187 (9.2)
>6 a 16	15	11	0	0	61	56	18	18	8	17	6	8	218/1,187 (18.4)
>16 a 31	9	13	0	0	56	66	12	21	14	44	2	6	243/1,187 (20.5)
>31	10	8	0	0	45	49	27	27	26	42	3	6	243/1,187 (20.5)
*not informed	0	0	0	0	0	0	0	0	1	1	0	0	2/1,187 (0.2)
Total	39	34	0	0	206	198	67	72	55	109	14	21	815/1,187 (68.7)

[7] Rodrigues et al. (2021); Age distribution: (Overall:  $\chi^2=8.2$ ;  $p=0.042$ ); (Xikrin:  $G=8.15$ ;  $p=0.0198$ ); (Araweté:  $\chi^2=12.3$ ;  $p=0.0065$ ); (Parakanã:  $\chi^2=3.9$ ;  $p=0.2753$ ); (Munduruku:  $\chi^2=23.8$ ;  $p<0.0001$ ); (Kararaô:  $G=4.4$ ;  $p=0.2213$ ). G - G test;  $\chi^2$  - Chi-square.

1  
2  
3  
4  
5  
6  
7 The main clinical manifestations reported among infected individuals were coughing,  
8  
9  
10 dyspnea, coryza, fever, fatigue, diarrhea, ear pain, headache, chest and back pain.  
11  
12

13  
14 There were seven deaths among the 815 infected persons showing a virulence rate of  
15  
16  
17 0.86%.  
18  
19  
20  
21  
22  
23

## 24 DISCUSSION

25  
26  
27  
28 The high prevalence of IgG anti-SARS-CoV-2 antibodies reported herein show that the  
29  
30  
31 new Coronavirus infection reached indigenous populations in a wide way. Introduction  
32  
33  
34 of new infectious agents among vulnerable indigenous peoples is thought to be a heavy  
35  
36  
37 burden because of the low genetic variability among genes that control the immune  
38  
39  
40 response,<sup>9</sup> an important element working as a selective pressure over indigenous  
41  
42  
43 peoples since the initial colonization process of the Amazon region of Brazil.  
44  
45  
46

47  
48  
49 SARS-CoV-2 brought the question again as to how the virus would affect native  
50  
51  
52 peoples? Despite the theoretical arguments for the possible speculative devastation of  
53  
54  
55 indigenous groups,<sup>6</sup> there was no confirmed evidence of susceptibility to Covid-19 in the  
56  
57  
58  
59  
60

1  
2  
3 presence of coinfections and pre-existing conditions, including obesity and malnutrition  
4  
5  
6  
7 as previously suggested.<sup>4 5</sup>  
8  
9

10 Most of the indigenous peoples of the Amazon region of Brazil, including those of the  
11  
12  
13 present study, present endemic diseases as malaria, tuberculosis, virus hepatitis and, to  
14  
15  
16  
17 HTLV-2 hyperendemic infections among Xikrin, Kararaô, Munduruku and Parakanã.<sup>10</sup>  
18  
19

20  
21 Presently, there is no scientific evidence for host modulation of SARS-CoV-2 in the  
22  
23  
24 presence of these coinfections, but researches in order to investigate these coinfections  
25  
26  
27 are of paramount importance for a better understanding of the outcome of SARS-CoV-2  
28  
29  
30  
31 infection. Furthermore, environmental and social conditions are important factors that  
32  
33  
34 could impact on COVID-19 among indigenous communities,<sup>3 4</sup> including the lack of  
35  
36  
37  
38 drinking water and malnutrition, which might had been potentialized after the  
39  
40  
41  
42 prophylactic isolation measures.  
43  
44

45 In our previous report the quality of tests to measure the presence of antibodies was  
46  
47  
48 raised.<sup>7</sup> It is important that antibodies to SARS-CoV-2 are detected using tests with  
49  
50  
51  
52 greater sensitivity and specificity to obtain accurate prevalence rates. Rapid tests  
53  
54  
55  
56 usually show low sensitivity and yield false negative results and false-positive results  
57  
58  
59

1  
2  
3 due to cross-reactions. In the present study, two methodologies were used and the  
4  
5  
6  
7 agreement of the results of the rapid test in relation to ELISA was good and the IgG  
8  
9  
10 prevalence values similar.

11  
12  
13  
14 In contrast to the genetic and socio-environmental vulnerability the results showed  
15  
16  
17 SARS-CoV-2 infection evenly distributed, with a high prevalence of the virus and few  
18  
19  
20 reported deaths, confirming the official results by Special Secretariat of Indigenous  
21  
22  
23 Health (SESAI) in its COVID-19 epidemiological bulletin.<sup>11</sup>

24  
25  
26  
27  
28 The prevalence of anti-SARS-CoV-2 IgG antibodies shows a high dissemination of the  
29  
30  
31 virus spread favored by inherent social and cultural difficulties of keeping social  
32  
33  
34 distance, sharing households with other families and wearing masks correctly

35  
36  
37  
38 The detection of IgM antibody in three villages might suggest recent infection in the  
39  
40  
41 villages. But the confirmation could only be done by antigen or nucleic acid tests, which  
42  
43  
44 were not available at the time of the study. Additionally, recent report has shown IgM  
45  
46  
47 persistence for up to 8 months post-Covid, pointing to the need for no longer using IgM  
48  
49  
50 as a diagnostic criterion

51  
52  
53  
54  
55  
56 for acute or recent COVID-19.<sup>12</sup>

1  
2  
3  
4 It is relevant to mention that three villages are more than 100Km apart from each other  
5  
6  
7 and there is no simple way of communication among them. This raises another  
8  
9  
10 important question in regard to herd protective immunity. Apparently, the communities  
11  
12  
13 achieved herd immunity levels, when reaching at least 60% seropositivity for IgG,<sup>13</sup>  
14  
15  
16 similarly as found in Manaus, the capital of the Amazonas State.<sup>14</sup> However, differently  
17  
18  
19 from what is seen among urban areas,<sup>15</sup> virgin soil epidemics generally exhaust  
20  
21  
22 susceptible individuals before it comes to an end,<sup>16</sup> and the present epidemic is still not  
23  
24  
25 totally explained and understood. The high seroprevalence of IgG anti-SARS-CoV-2  
26  
27  
28 antibodies reported herein among vulnerable Amazon Indigenous peoples, is  
29  
30  
31 comparable to our recent finding among Venezuelan indigenous Warao refugees  
32  
33  
34 residing in Belem city, the capital of Para State, where the infection was detected  
35  
36  
37 among 83% of the subjects living in conditions of vulnerability.<sup>17</sup> Similar results were  
38  
39  
40 reported among indigenous people living in the surrounding area of Manaus, where the  
41  
42  
43 number of individuals sharing households was a risk for virus infection.<sup>18</sup>  
44  
45  
46  
47  
48  
49  
50

51  
52 The results show new information over the SARS-CoV-2 epidemic among indigenous  
53  
54  
55 peoples and provides the Brazilian government with information to establish adequate  
56  
57  
58  
59  
60



1  
2  
3  
4 measures to control the epidemic among Brazilian indigenous communities in the  
5  
6  
7 Amazon region.  
8  
9

## 14 CONCLUSION

15  
16  
17 SARS-CoV-2 infection reached the indigenous populations from the State of Para as  
18  
19  
20 rapid as the virus entered the Amazon region, confirming our previous alert to the need  
21  
22  
23 of serological studies for surveillance, minimizing the burden of the epidemic and to  
24  
25  
26 promote indigenous health policies.<sup>5</sup>  
27  
28  
29

30  
31 In spite of the suggestion of high mortality and chaos facing the Amerindian  
32  
33  
34 populations,<sup>6</sup> the majority of the cases was asymptomatic or mild, with low fatality rate,  
35  
36  
37 supporting analysis that shows that the mortality associated with epidemics following  
38  
39  
40 contact of Amazonian indigenous communities with urban communities has decreased  
41  
42  
43  
44  
45 in recent years.<sup>19</sup>  
46  
47

48  
49 Finally, continuing seroepidemiological surveys are of paramount importance for  
50  
51  
52 monitoring the outcome of the national contingency plan for the prevention and control  
53  
54  
55

1  
2  
3 of the epidemic, by a mass vaccination program for indigenous peoples started by  
4  
5  
6  
7 February 2021.  
8  
9  
10  
11  
12  
13

14 **Acknowledgments** We thank the Indigenous populations for authorizing the study and  
15  
16  
17 the institutions that provided technical support for the development and implementation  
18  
19  
20 of this study. Our especial gratitude to Vilson Monteiro and Hailton Monteiro for  
21  
22  
23  
24 laboratorial assistance during the expeditions to Indigenous villages.  
25  
26  
27  
28  
29  
30

31 **Contributor** ACRV, JFG and RI: conception of idea, data analysis, writing and editing of  
32  
33  
34 manuscript; ACRV, RI, JFG, INA, BJSB and CNCL: Acquisition, analysis, or  
35  
36  
37 interpretation of data; CNCL, RI, IMVCV: Drafting of the manuscript; ACRV, RI, JFG  
38  
39  
40 and IMVCV: Critical revision of the manuscript for important intellectual content; SSL:  
41  
42  
43  
44  
45 Statistical analysis; ACRV: Obtained funding; VOF and EPSR: technical and material  
46  
47  
48  
49 support.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 **Funding** This study was supported by the National Council for Scientific and  
5  
6  
7 Technological Development (CNPq Project; MCTIC/CNPq/FNDCT/MS/SCTIE/DECIT n.  
8  
9  
10 401235/2020-3); Coordination for the Improvement of Higher Education Personnel  
11  
12  
13 (CAPES: 88887.612787/2021-00); and Federal University of Pará (UFPA-  
14  
15  
16  
17 PROESP/PAPQ-2021). CNPq Research Grants were received by ACRV (#-  
18  
19  
20  
21 301869/2017-0), RI (#312979/2018-5).  
22  
23  
24  
25  
26  
27

28 **Competing interests** None declared  
29  
30  
31  
32  
33  
34

35 **Patient and public involvement** Neither patients, parents nor the public were involved in  
36  
37  
38 the design, conduct or reporting of this research.  
39  
40  
41  
42  
43  
44

45 **Patient consent for publication** Not requirable  
46  
47  
48  
49  
50  
51

52 **Ethics approval** The study was approved by the leaders of the communities and by the  
53  
54  
55 National Research Ethics Committee (*Comissão Nacional de Ética em Pesquisa* –  
56  
57  
58  
59  
60

1  
2  
3 CONEP; CAAE: 33470020.0.1001.0018), in accordance with the Declarations of  
4  
5  
6  
7 Helsinki.  
8  
9  
10  
11  
12  
13

14 **Data availability statement** Data are available upon reasonable request  
15  
16 ([vallinoto@ufpa.br](mailto:vallinoto@ufpa.br))  
17  
18  
19  
20  
21  
22

## 23 REFERENCES

- 24  
25  
26  
27 1. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory  
28  
29  
30 disease in China. *Nature* 2020;579(7798):265-269.  
31  
32  
33  
34 <https://doi.org/10.1038/s41586-020-2008-3>.  
35  
36  
37 2. World Health Organization. Coronavirus disease (COVID-2019) situation reports;  
38  
39  
40  
41 2020. [https://www.who.int/emergencies/diseases/novel-coronavirus-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/)  
42  
43  
44 [2019/situation-reports/](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/) Accessed March 27, 2020.  
45  
46  
47 3. Fiocruz. 4º relatório sobre risco de espalhamento da COVID-19 em populações  
48  
49  
50  
51 indígenas. Risco de espalhamento da COVID-19 em populações indígenas:  
52  
53  
54  
55 considerações preliminares sobre vulnerabilidade geográfica e  
56  
57  
58  
59  
60

1  
2  
3 sociodemográfica. Available from:<https://portal.fiocruz.br/documento/4o-relatorio->  
4  
5  
6  
7 [sobre-risco-de-espalhamento-da-covid-19-em-populacoes-indigenas](https://portal.fiocruz.br/documento/4o-relatorio-sobre-risco-de-espalhamento-da-covid-19-em-populacoes-indigenas). Accessed  
8  
9  
10 June 27, 2020.

- 11  
12  
13  
14 4. Amigo I. Indigenous communities in Brazil fear pandemic's impact. *Science*.  
15  
16  
17 2020; 368(6489):352. <https://doi.org/10.1126/science.368.6489.352>.  
18  
19  
20  
21 5. Vallinoto ACR, da Silva Torres MK, Vallinoto MC, Cayres-Vallinoto, IMV. The  
22  
23  
24 challenges of COVID-19 in the Brazilian Amazonian communities and the  
25  
26  
27 importance of seroepidemiological surveillance studies. *Int J Equity Health*  
28  
29  
30 2020;19(1):140. <https://doi.org/10.1186/s12939-020-01256-7>  
31  
32  
33  
34  
35 6. Ramírez JD, Sordillo EM, Gotuzzo E, et al. SARS-CoV-2 in the Amazon region:  
36  
37  
38 A harbinger of doom for Amerindians. *PLoS Negl Trop Dis*.  
39  
40  
41 2020;14(10):e0008686. <https://doi.org/10.1371/journal.pntd.0008686>.  
42  
43  
44  
45 7. Rodrigues EPS, Abreu IN, Lima CNC, et al. High prevalence of anti-SARS-CoV-  
46  
47  
48 2 IgG antibody in the Xikrin of Bacajá (Kayapó) indigenous population in the  
49  
50  
51  
52 brazilian Amazon. *Int J Equity Health*. 2021;20(1):50.  
53  
54  
55  
56 <https://doi.org/10.1186/s12939-021-01392-8>.  
57  
58  
59  
60

- 1  
2  
3  
4 8. Ishak R, Guerreiro JF and Vallinoto ACR. Why Did They Not Die?. *Austin J*  
5  
6  
7 *Public Health Epidemiol.* 2021;8(3):1106.  
8  
9
- 10  
11 9. Dent R, Santos RV. An Unusual and Fast Disappearing Opportunity: Infectious  
12  
13  
14 Disease, Indigenous Populations, and New Biomedical Knowledge in Amazonia,  
15  
16  
17 1960-1970. *Perspect Sci.* 2017;25(5):585-605.  
18  
19  
20  
21 [https://doi.org/10.1162/POSC\\_a\\_00255](https://doi.org/10.1162/POSC_a_00255).  
22  
23
- 24  
25 10. Ishak R, Harrington WJ Jr, Azevedo VN, et al. Identification of human T cell  
26  
27  
28 lymphotropic virus type IIa infection in the Kayapo, an indigenous population of  
29  
30  
31 Brazil. *AIDS Res Hum Retroviruses.* 1995;11(7):813-21.  
32  
33  
34  
35 <https://doi.org/10.1089/aid.1995.11.813>.  
36  
37
- 38  
39 11. SESAI – Secretaria Especial de Saúde Indígena. Boletim epidemiológico SESAI  
40  
41  
42 – COVID-19. <http://www.saudeindigena.net.br/coronavirus/mapaEp.php>.  
43  
44  
45 Accessed April 12, 2021).  
46  
47
- 48  
49 12. Bichara CDA, Amoras ESG, Vaz GL, Bichara CNC, Amaral IPC, Vallinoto ACR.  
50  
51  
52 Persistence of Anti-SARS-CoV-2 IgM Antibody up to 8 Months Post-COVID-19.  
53  
54  
55  
56 *Case Rep Clin Med* 2021, 10, 227-231. <https://www.scirp.org/journal/crcm>.  
57  
58  
59


- 1  
2  
3  
4 13. Omer SB, Yildirim I, Forman HP. Herd Immunity and implications for SARS-  
5  
6  
7 CoV-2 control. *JAMA* 2020. <https://doi.org/10.1001/jama.2020.20892>.  
8  
9
- 10  
11 14. Buss LF, Prete CA Jr, Abraham CMM, et al. Three-quarters attack rate of SARS-  
12  
13  
14 CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. *Science*  
15  
16  
17 2020;8:eabe9728. <https://doi.org/10.1126/science.abe9728>.  
18  
19
- 20  
21 15. Hallal PC, Hartwig FP, Horta BL, et al. SARS-CoV-2 antibody prevalence in  
22  
23  
24 Brazil: results from two successive nationwide serological household surveys.  
25  
26  
27 *Lancet Glob Health*. 2020;8(11):e1390-e1398. <https://doi.org/10.1016/S2214->  
28  
29  
30  
31 109X(20)30387-9.  
32  
33
- 34  
35 16. Crosby AW. Virgin soil epidemics as a factor in the aboriginal depopulation in  
36  
37  
38 America. *William Mary Q*. 1976;33:289-99. PMID: 11633588.  
39  
40
- 41  
42 17. da Silva HP, Abreu IN, Lima CNC, et al. Migration in times of pandemic: SARS-  
43  
44  
45 CoV-2 infection among the Warao indigenous refugees in Belém, Pará,  
46  
47  
48 Amazonia, Brazil. *BMC Public Health*. 2021;21(1):1659. doi: 10.1186/s12889-  
49  
50  
51 021-11696-7.  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 18. Pontes GS, de Melo Silva J, Pinheiro-Silva R, Barbosa AN, Santos LC, de  
5  
6  
7 Pádua Quirino Ramalho A, de Castro Alves CE, da Silva DF, de Oliveira LC, da  
8  
9  
10 Costa AG, Bruno AC. Increased vulnerability to SARS-CoV-2 infection among  
11  
12  
13 indigenous people living in the urban area of Manaus. *Sci Rep.*  
14  
15  
16 2021;11(1):17534. doi: 10.1038/s41598-021-96843-1.  
17  
18  
19  
20  
21 19. Walker RS, Sattenspiel L, Hill KR. Mortality from contact-related epidemics  
22  
23  
24 among indigenous populations in Greater Amazonia. *Sci Rep.* 2015;5:14032.  
25  
26  
27  
28 <https://doi.org/10.1038/srep14032>.  
29  
30  
31  
32  
33  
34

35 Figure Legend.

36  
37  
38 **Figure 1.** Map showing the geographical location of the indigenous communities  
39  
40  
41 investigated enrolled in the present study.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





296x209mm (600 x 600 DPI)

# BMJ Open

## Anti-SARS-CoV-2 antibodies among indigenous populations of the Brazilian Amazon: a cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-054271.R3
Article Type:	Original research
Date Submitted by the Author:	06-Jan-2022
Complete List of Authors:	Lima, Carlos Neandro ; Universidade Federal do Para Abreu, Isabella; Universidade Federal do Pará Rodrigues, Eliene Putira; Universidade Federal do Para Freitas, Vanessa; Universidade Federal do Pará Botelho, Bruno José ; Universidade Federal do Para Souza, Sandra; Universidade Federal do Para Cayres-Vallinoto, Izaura; Universidade Federal do Para Guerreiro, João; Universidade Federal do Para Ishak, Ricardo; Universidade Federal do Para Vallinoto, Antonio; Universidade Federal do Para
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Global health, Infectious diseases, Immunology (including allergy), Public health
Keywords:	COVID-19, EPIDEMIOLOGY, INFECTIOUS DISEASES

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 1 **Anti-SARS-CoV-2 antibodies among indigenous populations of the Brazilian Amazon: a**  
5  
6  
7 2 **cross-sectional study**  
8  
9  
10  
11 3  
12  
13

14 4 Carlos Neandro Cordeiro Lima,<sup>1</sup> Isabella Nogueira Abreu,<sup>1</sup> Eliene Putira Sacuena

15  
16  
17 5 Rodrigues,<sup>2</sup> Vanessa de Oliveira Freitas,<sup>1</sup> Bruno José Sarmiento Botelho,<sup>1</sup> Sandra

18  
19  
20  
21 6 Souza Lima,<sup>1</sup> Izaura Maria Vieira Cayres Vallinoto,<sup>1</sup> João Farias Guerreiro,<sup>\* 2</sup> Ricardo

22  
23  
24 7 Ishak,<sup>\*1</sup> Antonio Carlos Rosário Vallinoto<sup>\*1</sup>  
25  
26  
27  
28 8

29  
30  
31 9 <sup>1</sup> Laboratório de Virologia, Instituto de Ciências Biológicas da Universidade Federal do

32  
33  
34  
35 10 Pará, Belém, PA, Brasil;

36  
37  
38 11 <sup>2</sup> Laboratório de Genética Humana e Médica, Instituto de Ciências Biológicas da

39  
40  
41  
42 12 Universidade Federal do Pará, Belém, PA, Brasil.  
43  
44  
45 13

46  
47  
48 14 \* RI, JFG and ACRV are senior authors of the manuscript  
49  
50  
51  
52 15

53  
54  
55  
56 16 **Correspondence to Dr. Antonio Carlos Rosário Vallinoto; [vallinoto@ufpa.br](mailto:vallinoto@ufpa.br)**  
57  
58  
59  
60

17

**ABSTRACT**

**Objectives** The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its pandemic spread generated serious concern about the impact of the infection on vulnerable indigenous populations of the Brazilian Amazon. Thus, the present study aimed to perform a seroepidemiological survey of anti-SARS-CoV-2 antibodies in those populations.

**Setting** Six indigenous ethnic groups living in the State of Pará (Northern Brazil) were investigated. The villages of Xikrin do Bacajá, Assurini, Araweté, Parakanã, Munduruku and Kararaô were visited from October 2020 to January 2021.

**Design and participants** We performed a cross-sectional study to investigate the prevalence of anti-spike (S1) IgG antibodies. Plasma was tested for the presence of anti-SARS-CoV-2 IgM and IgG antibodies using two assays (a lateral flow rapid test and an ELISA). A total of 1,185 individuals of both sexes were enrolled in the study.

**Results** The prevalence of IgM and IgG antibodies were 6.9% and 68.1%, respectively, ranging from 0% to 79.6%, with significant differences ( $p < 0.001$ ) between age groups in

1  
2  
3  
4 33 three communities (Araweté, Xikrin and Munduruku) and a virulence rate of 0.86%. The  
5  
6  
7 34 overall IgG prevalence obtained by rapid tests and ELISAs were similar, and the  
8  
9  
10 35 agreement of the results between the two tests was 80%, which was classified as good  
11  
12  
13  
14 36 ( $\kappa=0.4987$ ;  $p<0.001$ ; sensitivity of 82.1% and specificity of 71.6%). Herd immunity  
15  
16  
17 37 was probably attained, similar to that found in other communities of the Amazon.

18  
19  
20  
21 38 **Conclusions** SARS-CoV-2 spread rapidly among the indigenous populations  
22  
23  
24 39 investigated, but it had a low mortality rate. It is necessary to expand serological  
25  
26  
27  
28 40 investigations to other communities in the Amazon region of Brazil.  
29  
30

31 41  
32  
33  
34  
35 42 **Keywords:** SARS-CoV-2, COVID-19, Indigenous peoples, Amazon.  
36  
37  
38  
39 43  
40  
41  
42 44  
43  
44  
45 45  
46  
47  
48  
49 46 **Strengths and limitations of this study**  
50  
51

- 52 47 • The sample size of the present study was high and representative of the  
53  
54  
55  
56 48 populations.  
57  
58  
59  
60

- 49 • Serological tests of high sensitivity and specificity were used in the present study.
- 50 • Failure to assess infection by RT-PCR was a limitation of the study.

51

## 52 INTRODUCTION

53 Infection with novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)  
54 and the first cases of coronavirus disease 2019 (COVID-19) were reported by  
55 November 2019 in Wuhan, China.<sup>1</sup> The rapid spread of the virus determined its  
56 classification as a pandemic by the World Health Organization (WHO)<sup>2</sup>, and the high  
57 associated morbimortality highlighted the burden imposed on vulnerable populations,  
58 including native indigenous peoples living in the Brazilian Amazon who were susceptible  
59 to the virus and could be substantially affected due to their immunological vulnerability.<sup>3-</sup>  
60 <sup>6</sup> Three previous reports from our laboratory highlight the distinct cultural (sharing  
61 households) and health aspects (coinfections and malnutrition) and mode of infection  
62 among these Amazonian populations, the impact of the virus among native people, and

1  
2  
3  
4 63 the importance of performing serosurveys among such populations to determine the  
5  
6  
7 64 spectrum of illness.<sup>5 7 8</sup>  
8  
9

10 65 Due to the vulnerability of indigenous people who inhabit the Brazilian Amazon region  
11  
12  
13  
14 66 and their supposed inability to respond immunologically to new pathogens that emerge  
15  
16  
17 67 in the community, the following question was asked: What was the impact of SARS-  
18  
19  
20  
21 68 CoV-2 infection on indigenous people living in the Brazilian Amazon region? Assuming  
22  
23  
24 69 the possible negative impact that the COVID-19 pandemic may have had on these  
25  
26  
27  
28 70 communities, in this study, we carried out a seroepidemiological investigation in  
29  
30  
31 71 indigenous populations located in the State of Pará by performing anti-SARS-CoV-2  
32  
33  
34  
35 72 antibody screening.  
36  
37  
38  
39 73  
40  
41

## 42 74 **METHODS**

### 45 75 **Type of study and ethical considerations**

46  
47  
48  
49 76 In 2020, a large cross-sectional seroepidemiological surveillance study among  
50  
51  
52 77 indigenous ethnic groups within Para State (Northern Brazil, Amazon) was initiated to  
53  
54  
55  
56 78 investigate the prevalence of anti-SARS-CoV-2 IgM and IgG antibodies and the impact  
57  
58  
59



1  
2  
3  
4 79 of the virus on the health of communities. The study was approved by the leaders of the  
5  
6  
7 80 communities and by the National Research Ethics Committee (*Comissão Nacional de*  
8  
9  
10 81 *Ética em Pesquisa* – CONEP; CAAE: 33470020.0.1001.0018), in accordance with the  
11  
12  
13  
14 82 Declarations of Helsinki.

### 84 **Study population**

85 From October 2020 to January 2021, multiprofessional health care expeditions,  
86 composed of members of our team and staff of the Health Department of the State of  
87 Para (*Secretaria de Saúde do Estado do Pará – SESPA*) and the Special Indigenous  
88 Health Districts of Altamira and Santarém (*Distrito Sanitário Especial Indígena – DSEI*)  
89 of the Special Secretariat of Indigenous Health (*Secretaria Especial de Saúde Indígena*  
90 – *SESAI-MS*), were established. Six ethnic groups with active cases of COVID-19 in  
91 members were visited before initiation of the vaccination campaign among indigenous  
92 communities. Indigenous individuals underwent a standard clinical examination that was  
93 performed under field conditions; the examination consisted of anamnesis and a  
94 physical examination (inspection, palpation, percussion and auscultation), with

1  
2  
3  
4 95 assessments of anthropometric, blood pressure, body temperature and digital oximetry  
5  
6  
7 96 data. Laboratory support was provided for blood counts and biochemical,  
8  
9  
10 97 microbiological and parasitological exams.

11  
12  
13  
14 98 The villages of the indigenous people of the basin of the middle Xingu River (Asurini,  
15  
16  
17 99 Araweté and Parakanã), Iriri River (Kararaô) and Tapajós River (Munduruku) are  
18  
19  
20  
21 100 usually accessed by the river, while the village of the Xikrin people, located in the  
22  
23  
24 101 Bacajá River channel, are accessed by road (Figure 1). The indigenous people studied  
25  
26  
27  
28 102 were as follows:

29  
30  
31 103 (i) Araweté: a Tupi-Guarani-speaking population of 589 inhabitants who are currently  
32  
33  
34  
35 104 distributed in 22 villages, with populations from 7 to 71 individuals. Villages are located  
36  
37  
38 105 on the banks of the Xingú River and the Ipixuna stream (-4,8853, -52,4281) and the  
39  
40  
41  
42 106 right bank tributary of the middle Xingu River, in the municipality of Altamira (PA). A total  
43  
44  
45 107 of 508 people from all villages were examined.

46  
47  
48  
49 108 (ii) Asurini do Xingu: from the Tupi-Guarani family, with 260 individuals distributed in five  
50  
51  
52 109 villages on the banks of the middle Xingu River (-4,2449, -52,2380); eight people from  
53  
54  
55  
56 110 the Kwatinemu village (n = 139) were examined.

- 1  
2  
3  
4 111 (iii) Parakanã: indigenous Tupi-Guarani people who live in the Apyterewa land, in the  
5  
6  
7 112 municipalities of Altamira and São Félix do Xingu, in the Xingu basin (-5,6904, -  
8  
9  
10 113 52,0037), Pará. The total population is 782 people distributed in 16 small villages, with  
11  
12  
13  
14 114 populations ranging from 17 to 94 individuals. Two hundred ten people were examined.  
15  
16  
17 115 (iv) Xikrin do Bacajá: people who speak the Kayapó (or Mebengokré) language, Jê  
18  
19  
20  
21 116 linguistic family, and live in 19 small villages (populations from 11 to 141 individuals;  
22  
23  
24 117 current population of 1,051 inhabitants) in the middle Bacajá basin (-3.7160, -53.0546)  
25  
26  
27  
28 118 and municipalities of Senador José Porfírio and Anapú, PA. One hundred individuals  
29  
30  
31 119 from seven villages were examined: Kenkrô (39/61), Bakajá (23/109), Mrotdjam (1/128),  
32  
33  
34  
35 120 Pykatum (4/59), Rapkô (7/60), Pytatko (1941) and Moinorô (13/77);  
36  
37  
38 121 (v) Kararaô: another Jê-speaking Kayapó subgroup distributed in four small villages  
39  
40  
41  
42 122 (Kararaô, n = 15; Kruakrô, n = 15; Pidjôdjã, n = 42 and Rikrekô, n = 11) located in the  
43  
44  
45 123 lower Iriri River and in the middle Xingu River (-3,9112, -52,8044), Altamira, PA. Forty-  
46  
47  
48  
49 124 four individuals were examined among a total population of 83 individuals.  
50  
51  
52 125 (vi) Munduruku: an indigenous population belonging to the Munduruku linguistic family  
53  
54  
55  
56 126 of the Tupi language trunk who lives in southwestern Pará in the Tapajós River channel  
57  
58  
59  
60

1  
2  
3  
4 127 and tributaries in the municipalities of Santarém, Itaituba and Jacareacanga (-3.9112, -  
5  
6  
7 128 52.8044). The total population of 10,629 is distributed in 133 villages. A total of 317  
8  
9  
10  
11 129 individuals were examined: 213 from Nova Karapanatuba village (213/414) and 201  
12  
13  
14 130 from smaller villages around Nova Karapanatuba in Jacareacanga, PA.

131

### 132 **Anti-SARS-CoV-2 antibody assays**

133 A blood sample (5 mL) was collected, and the plasma was tested for the presence of  
134 anti-SARS-CoV-2 IgM and IgG antibodies. Anti-SARS-CoV-2 IgM and IgG antibodies  
135 were detected using a rapid test (lateral flow method; Guangzhou Wondfo Biotech Co.,  
136 China) and an enzyme-linked immunosorbent assay (ELISA; Anti-SARS-CoV-2 S1 IgG,  
137 Euroimmun, Brazil), respectively, according to the manufacturers' recommendations.

### 138 **Data analysis**

139 The Kappa test was used to assess the agreement between the rapid test and ELISA  
140 results. G and chi-square tests were performed to assess difference in the prevalence  
141 of IgG among the villages in relation to sex and age.

1  
2  
3  
4 142 We estimated the virulence rate as the number of deaths in each village divided by the  
5  
6  
7 143 number of individuals who were infected with SARS-CoV-2, according to IgG  
8  
9  
10 144 seropositivity.  
11  
12  
13  
14 145

### 17 146 **Patient and public involvement**

19  
20  
21 147 The study subjects, parents of study subjects or the public had no involvement in the  
22  
23  
24 148 design, conduct or reporting of this research.  
25  
26  
27  
28 149

## 31 150 **RESULTS**

32  
33  
34  
35 151 A total of 1,187 subjects were investigated, including 552 males (46.5%) and 635  
36  
37  
38 152 females (53.5%). The ages ranged from 1 to 95 years old (mean of 26.2, standard  
39  
40  
41  
42 153 deviation of 19.9 years).  
43  
44

45 154 Anti-SARS-CoV-2 IgG was detected in 505 (68.1%) individuals by rapid tests and 815  
46  
47  
48  
49 155 (68.7%) individuals by ELISAs (Table 1). Eight Asurini individuals were negative for  
50  
51  
52 156 antibodies, but among the other indigenous populations, antibody positivity (by ELISA)  
53  
54  
55  
56 157 ranged from 51.7% (Munduruku) to 79.5% (Araweté and Kararaô). The overall IgG  
57  
58  
59  
60

1  
2  
3  
4 158 prevalence obtained by rapid tests and ELISAs were similar, and the agreement of the  
5  
6  
7 159 results between the two tests was 80%, which was classified as good (kappa=0.4987;  
8  
9  
10 160 p<0.001; sensitivity of 82.1% and specificity of 71.6%). Thirty-three (2.8%) individuals  
11  
12  
13  
14 161 had indeterminate anti-SARS-CoV-2 IgG antibody results by ELISA. Additionally, IgM  
15  
16  
17 162 antibodies were detected in 51 (6.9%) individuals from three villages.  
18  
19  
20  
21 163 There was no significant difference in the IgG prevalence between the sexes (overall:  $\chi^2$   
22  
23  
24 164 =0.001, p=0.9793; Xikrin:  $\chi^2= 0.056$ , p=0.8129; Araweté:  $\chi^2=0.003$ , p=0.9554;  
25  
26  
27  
28 165 Parakanã:  $\chi^2=1.022$ , p=0.3121; Munduruku:  $\chi^2=1.496$ , p=0.2213; Kararaô:  $\chi^2=0.0278$ ,  
29  
30  
31 166 p=0.0642). Regarding age, in Araweté and Xikrin, the prevalences were significantly  
32  
33  
34  
35 167 lower among those >31 years old (p=0.0065 and p=0.0198), and in Munduruku, the  
36  
37  
38 168 prevalence was lower among those aged <6 years (p<0.0001) and more than 31 years  
39  
40  
41  
42 169 (Table 2).  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

170 **Table 1.** Prevalence of anti-SARS-CoV-2 (S1) IgG antibodies among indigenous populations by village

Population	Age range	Sex		Rapid test results			ELISA IgG anti-spike S1 results			N Deaths		
		Male N (%)	Female N (%)	N tested	Negative N (%)	IgM N (%)	IgG N (%)	N tested	Negative N (%)		Ind N (%)	IgG N (%)
Xikrin do Bacajá <sup>[7]</sup>	2 y to 84 y	51 (51.0)	49 (49.0)	100	42 (42)	nt	58 (58)	100	27 (27)	0 (0)	73 (73)	01
Asurini	17 y to 42 y	0 (0)	8 (100)	0	nt	nt	nt	08	7 (87.5)	1 (12.5)	0 (0)	0
Araweté	8 m to 84 y	258 (50.8)	250 (49.2)	236	29 (12.3)	11 (4.7)	196 (83)	508	92 (18.1)	12 (2.4)	404 (79.5)	0
Parakanã	7 m to 95 y	106 (50.5)	104 (49.5)	195	06 (3.1)	39 (20)	150 (76.9)	210	65 (30.9)	06 (2.8)	139 (66.2)	01
Munduruku	7 m to 89 y	116 (36.6)	201 (63.4)	166	96 (57.8)	nt	70 (42.2)	317	139 (43.9)	14 (4.4)	164 (51.7)	05
Kararaô	1 y to 94 y	21 (47.7)	23 (52.3)	44	13 (29.5)	1 (2.3)	30 (68.2)	44	9 (20.4)	0 (0)	35 (79.5)	0
Total	7 m to 95 y	552 (46.5)	635 (53.5)	741	185 (25.0)	51 (6.9)	505 (68.1)	1.187	339 (28.5)	33 (2.8)	815 (68.7)	07

171 m (months); y (years), nt (not tested); [7] Rodrigues et al. (2021); Ind: Indeterminate

172

173

174

175

176 **Table 2.** Anti-SARS-CoV-2 (S1) IgG antibodies among indigenous villages by age and sex

Age (y)	Xikrin <sup>[7]</sup>		Asurini		Araweté		Parakanã		Munduruku		Kararaô		Total
	male	female	male	female	male	female	male	female	male	female	male	female	n/total (%)
0-6	5	2	0	0	44	27	10	6	6	5	3	1	109/1,187 (9.2)
>6 to 16	15	11	0	0	61	56	18	18	8	17	6	8	218/1,187 (18.4)
>16 to 31	9	13	0	0	56	66	12	21	14	44	2	6	243/1,187 (20.5)
>31	10	8	0	0	45	49	27	27	26	42	3	6	243/1,187 (20.5)
*not informed	0	0	0	0	0	0	0	0	1	1	0	0	2/1,187 (0.2)
Total	39	34	0	0	206	198	67	72	55	109	14	21	815/1,187 (68.7)

177 [7] Rodrigues et al. (2021); Age distribution: (Overall:  $\chi^2=8.2$ ;  $p=0.042$ ); (Xikrin:  $G=8.15$ ;  $p=0.0198$ ); (Araweté:  $\chi^2=12.3$ ;  $p=0.0065$ ); (Parakanã:  $\chi^2=3.9$ ;  $p=0.2753$ );

178 (Munduruku:  $\chi^2=23.8$ ;  $p<0.0001$ ); (Kararaô:  $G=4.4$ ;  $p=0.2213$ ). G - G test;  $\chi^2$  - chi-square.



179

180 The main clinical manifestations reported among infected individuals were coughing,

181 dyspnea, coryza, fever, fatigue, diarrhea, ear pain, headache, and chest and back pain.

182 There were seven deaths among 815 infected persons, resulting in a virulence rate of

183 0.86%.

184

## 185 DISCUSSION

186 The high prevalence of IgG anti-SARS-CoV-2 antibodies reported herein shows that

187 novel coronavirus infection broadly impacted indigenous populations. The introduction

188 of new infectious agents among vulnerable indigenous populations is thought to impose

189 a heavy burden because of the low genetic variability among genes that control the

190 immune response,<sup>9</sup> an important selective pressure in indigenous people since the

191 initial colonization of the Amazon region of Brazil.

192 The pandemic raised the question of how SARS-CoV-2 would affect native peoples.

193 Despite theoretical arguments for the possible devastation of indigenous groups,<sup>6</sup> there

194 was no confirmed evidence of susceptibility to SARS-CoV-2 infection in the presence of

1  
2  
3  
4 195 coinfections or pre-existing conditions, including obesity and malnutrition, as previously  
5  
6  
7 196 suggested.<sup>4 5</sup>  
8  
9

10 197 Most of the indigenous people of the Amazon region of Brazil, including some of those  
11  
12  
13  
14 198 in the present study, namely the Xikrin, Kararaô, Munduruku and Parakanã, are  
15  
16  
17 199 continuously exposed to endemic diseases such as malaria, tuberculosis, virus hepatitis  
18  
19  
20  
21 200 and HTLV-2 hyperendemic infections.<sup>10</sup> Presently, there is no scientific evidence of host  
22  
23  
24 201 modulation of SARS-CoV-2 in the presence of these coinfections, but research to  
25  
26  
27  
28 202 investigate these coinfections is of paramount importance to better understand of the  
29  
30  
31 203 outcomes of SARS-CoV-2 infection. Furthermore, environmental and social conditions,  
32  
33  
34  
35 204 including a lack of drinking water and malnutrition, are important factors that could  
36  
37  
38 205 impact COVID-19 dynamics among indigenous communities,<sup>3 4</sup> and these factors might  
39  
40  
41  
42 206 have been potentiated after prophylactic isolation measures.  
43  
44

45 207 In our previous report, the quality of tests to measure the presence of antibodies was  
46  
47  
48 208 analyzed.<sup>7</sup> It is important that antibodies to SARS-CoV-2 are detected using tests with  
49  
50  
51  
52 209 good sensitivity and specificity to obtain accurate prevalence rates. Rapid tests usually  
53  
54  
55  
56 210 have low sensitivity and yield false-negative or false-positive results due to cross-

1  
2  
3  
4 211 reactions. In the present study, two methodologies were used; the agreement of the  
5  
6  
7 212 results between the rapid test and ELISA was good, and the IgG prevalence values  
8  
9  
10 213 were similar.

11  
12  
13  
14 214 The results showed that SARS-CoV-2 infections were evenly distributed, with a high  
15  
16  
17 215 viral prevalence but few reported deaths, despite genetic and socioenvironmental  
18  
19  
20  
21 216 vulnerability, confirming the official results of the COVID-19 Epidemiological Bulletin  
22  
23  
24 217 published by the Special Secretariat of Indigenous Health (SESAI).<sup>11</sup>

25  
26  
27  
28 218 The prevalence of anti-SARS-CoV-2 IgG antibodies indicated wide dissemination of the  
29  
30  
31 219 virus, caused by inherent social and cultural challenges in social distancing, household  
32  
33  
34  
35 220 isolation and mask wearing.

36  
37  
38 221 The detection of IgM antibodies in three villages might suggest recent infection in these  
39  
40  
41  
42 222 villages. However, IgM positivity can be confirmed by only antigen or nucleic acid tests,  
43  
44  
45 223 which were not available at the time of the study. Additionally, a recent report showed  
46  
47  
48  
49 224 IgM persistence for up to 8 months post-SARS-CoV-2 infection, suggesting that IgM  
50  
51  
52 225 positivity should no longer be considered a diagnostic criterion to confirm acute or  
53  
54  
55  
56 226 recent SARS-CoV-2 infection.<sup>12</sup>

1  
2  
3  
4 227 Notably, three villages are located more than 100 km away from each other, and there  
5  
6  
7 228 is no simple method of communication among them. This raises another important  
8  
9  
10 229 question regarding herd immunity. Apparently, the communities achieved herd immunity  
11  
12  
13  
14 230 when at least 60% IgG seropositivity was reached,<sup>13</sup> similar to that in Manaus, the  
15  
16  
17 231 capital of Amazonas State.<sup>14</sup> However, unlike in urban areas,<sup>15</sup> in rural areas, virgin soil  
18  
19  
20  
21 232 epidemics generally affect most susceptible individuals before the epidemic ends,<sup>16</sup> and  
22  
23  
24 233 the dynamics of the present epidemic are still not completely understood. The high  
25  
26  
27  
28 234 seroprevalence of IgG anti-SARS-CoV-2 antibodies reported herein among vulnerable  
29  
30  
31 235 Amazon indigenous peoples is comparable to our recent finding among Venezuelan  
32  
33  
34  
35 236 indigenous Warao refugees residing in Belem city, the capital of Para state, where  
36  
37  
38 237 infection was detected in 83% of the subjects.<sup>17</sup> Similar results were reported among  
39  
40  
41  
42 238 indigenous people living in the surrounding area of Manaus, where the number of  
43  
44  
45 239 individuals sharing households was a risk for virus infection.<sup>18</sup>  
46  
47  
48  
49 240 The main limitation of our study was that it was not possible to assess the presence of  
50  
51  
52 241 SARS-CoV-2 infection by RT-qPCR at the time of visits to the villages, but the results  
53  
54  
55  
56 242 provide new information about the SARS-CoV-2 epidemic among indigenous peoples  
57  
58  
59  
60

1  
2  
3  
4 243 and can provide the Brazilian government with information to establish adequate  
5  
6  
7 244 epidemic control measures among Brazilian indigenous communities in the Amazon  
8  
9  
10  
11 245 region.

12  
13  
14 246

## 17 247 **CONCLUSION**

20  
21 248 SARS-CoV-2 infection rapidly spread among indigenous populations in the state of Para  
22  
23  
24 249 in the Amazon region, supporting our previous call for serological surveillance studies to  
25  
26  
27  
28 250 minimize the of burden the epidemic and promote indigenous health policies.<sup>5</sup>

29  
30  
31 251 Despite the suggestion of high mortality and morbidity among Amerindian populations,<sup>6</sup>  
32  
33  
34  
35 252 the majority of cases were asymptomatic or mild, with a low fatality rate, supporting the  
36  
37  
38 253 suggestion that mortality associated with epidemics that spread from urban  
39  
40  
41  
42 254 communities to Amazonian indigenous communities has decreased in recent years.<sup>19</sup>

43  
44  
45 255 Finally, continuing seroepidemiological surveys is of paramount importance in  
46  
47  
48  
49 256 monitoring the outcome of the national contingency plan for the prevention and control  
50  
51  
52 257 of the epidemic, which includes a mass vaccination program for indigenous peoples,  
53  
54  
55  
56 258 started in February 2021.

1  
2  
3  
4 259

5  
6  
7 260 **Acknowledgments** We thank the indigenous populations for authorizing the study and  
8  
9  
10 261 the institutions that provided technical support for the development and implementation  
11  
12  
13  
14 262 of this study. We are especially grateful to Vilson Monteiro and Hailton Monteiro for  
15  
16  
17 263 laboratorial assistance during the expeditions to indigenous villages.  
18  
19  
20

21 264

22  
23  
24 265 **Contributors** ACRV, JFG and RI: study conception, data analysis, manuscript writing  
25  
26  
27  
28 266 and editing; ACRV, RI, JFG, INA, BJSB and CNCL: acquisition, analysis, or  
29  
30  
31 267 interpretation of the data; CNCL, RI, IMVCV: drafting of the manuscript; ACRV, RI, JFG  
32  
33  
34  
35 268 and IMVCV: critical revision of the manuscript for important intellectual content; SSL:  
36  
37  
38 269 statistical analysis; ACRV: obtained funding; VOF and EPSR: technical and material  
39  
40  
41  
42 270 support.  
43  
44

45 271

46  
47  
48  
49 272 **Funding** This study was supported by the National Council for Scientific and  
50  
51  
52 273 Technological Development (CNPq Project; MCTIC/CNPq/FNDCT/MS/SCTIE/DECIT n.  
53  
54  
55  
56 274 401235/2020-3); Coordination for the Improvement of Higher Education Personnel  
57  
58  
59

1  
2  
3  
4 275 (CAPES: 88887.612787/2021-00); and Federal University of Pará (UFPA-  
5  
6  
7 276 PROPESP/PAPQ-2021). CNPq Research Grants were received by ACRV (#-  
8  
9  
10 277 301869/2017-0) and RI (#312979/2018-5).  
11  
12

13  
14 278

15  
16  
17 279 **Competing interests** None declared  
18  
19

20  
21 280

22  
23  
24 281 **Patient and public involvement** The study subjects, parents of the study subjects or the  
25  
26  
27  
28 282 public were not involved in the design, conduct or reporting of this research.  
29  
30

31 283

32  
33  
34  
35 284 **Patient consent for publication** Not requirable  
36  
37

38 285

39  
40  
41  
42 286 **Ethics approval** The study was approved by the leaders of the communities and by the  
43  
44  
45 287 National Research Ethics Committee (*Comissão Nacional de Ética em Pesquisa* –  
46  
47  
48 288 CONEP; CAAE: 33470020.0.1001.0018), in accordance with the Declarations of  
49  
50  
51  
52 289 Helsinki.  
53  
54

55  
56 290  
57  
58  
59  
60

1  
2  
3  
4 291 **Data availability statement** Data are available upon reasonable request  
5  
6 292 ([vallinoto@ufpa.br](mailto:vallinoto@ufpa.br))  
7  
8  
9

10 293

11  
12  
13 294 **REFERENCES**  
14  
15

- 16 295 1. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory  
17  
18  
19  
20 296 disease in China. *Nature* 2020;579(7798):265-269.  
21  
22  
23 297 <https://doi.org/10.1038/s41586-020-2008-3>.  
24  
25  
26  
27 298 2. World Health Organization. Coronavirus disease (COVID-2019) situation reports;  
28  
29  
30 299 2020. [https://www.who.int/emergencies/diseases/novel-coronavirus-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/)  
31  
32  
33 300 [2019/situation-reports/](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/) Accessed March 27, 2020.  
34  
35  
36  
37 301 3. Fiocruz. 4º relatório sobre risco de espalhamento da COVID-19 em populações  
38  
39  
40 302 indígenas. Risco de espalhamento da COVID-19 em populações indígenas:  
41  
42  
43 303 considerações preliminares sobre vulnerabilidade geográfica e  
44  
45  
46  
47 304 sociodemográfica. Available from:[https://portal.fiocruz.br/documento/4o-relatorio-](https://portal.fiocruz.br/documento/4o-relatorio-sobre-risco-de-espalhamento-da-covid-19-em-populacoes-indigenas)  
48  
49  
50 305 [sobre-risco-de-espalhamento-da-covid-19-em-populacoes-indigenas](https://portal.fiocruz.br/documento/4o-relatorio-sobre-risco-de-espalhamento-da-covid-19-em-populacoes-indigenas). Accessed  
51  
52  
53  
54 306 June 27, 2020.  
55  
56  
57  
58  
59  
60



- 1  
2  
3  
4 307 4. Amigo I. Indigenous communities in Brazil fear pandemic's impact. *Science*.  
5  
6  
7 308 2020; 368(6489):352. <https://doi.org/10.1126/science.368.6489.352>.  
8  
9  
10 309 5. Vallinoto ACR, da Silva Torres MK, Vallinoto MC, Cayres-Vallinoto, IMV. The  
11  
12  
13  
14 310 challenges of COVID-19 in the Brazilian Amazonian communities and the  
15  
16  
17 311 importance of seroepidemiological surveillance studies. *Int J Equity Health*  
18  
19  
20  
21 312 2020;19(1):140. <https://doi.org/10.1186/s12939-020-01256-7>  
22  
23  
24 313 6. Ramírez JD, Sordillo EM, Gotuzzo E, et al. SARS-CoV-2 in the Amazon region:  
25  
26  
27  
28 314 A harbinger of doom for Amerindians. *PLoS Negl Trop Dis*.  
29  
30  
31 315 2020;14(10):e0008686. <https://doi.org/10.1371/journal.pntd.0008686>.  
32  
33  
34  
35 316 7. Rodrigues EPS, Abreu IN, Lima CNC, et al. High prevalence of anti-SARS-CoV-  
36  
37  
38 317 2 IgG antibody in the Xikrin of Bacajá (Kayapó) indigenous population in the  
39  
40  
41  
42 318 brazilian Amazon. *Int J Equity Health*. 2021;20(1):50.  
43  
44  
45 319 <https://doi.org/10.1186/s12939-021-01392-8>.  
46  
47  
48  
49 320 8. Ishak R, Guerreiro JF and Vallinoto ACR. Why Did They Not Die?. *Austin J*  
50  
51  
52 321 *Public Health Epidemiol*. 2021;8(3):1106.  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 322 9. Dent R, Santos RV. An Unusual and Fast Disappearing Opportunity: Infectious  
5  
6  
7 323 Disease, Indigenous Populations, and New Biomedical Knowledge in Amazonia,  
8  
9  
10 324 1960-1970. *Perspect Sci*. 2017;25(5):585-605.  
11  
12  
13  
14 325 [https://doi.org/10.1162/POSC\\_a\\_00255](https://doi.org/10.1162/POSC_a_00255).  
15  
16  
17 326 10. Ishak R, Harrington WJ Jr, Azevedo VN, et al. Identification of human T cell  
18  
19  
20  
21 327 lymphotropic virus type IIa infection in the Kayapo, an indigenous population of  
22  
23  
24 328 Brazil. *AIDS Res Hum Retroviruses*. 1995;11(7):813-21.  
25  
26  
27  
28 329 <https://doi.org/10.1089/aid.1995.11.813>.  
29  
30  
31 330 11. SESAI – Secretaria Especial de Saúde Indígena. Boletim epidemiológico SESAI  
32  
33  
34  
35 331 – COVID-19. <http://www.saudeindigena.net.br/coronavirus/mapaEp.php>.  
36  
37  
38 332 Accessed April 12, 2021).  
39  
40  
41  
42 333 12. Bichara CDA, Amoras ESG, Vaz GL, Bichara CNC, Amaral IPC, Vallinoto ACR.  
43  
44  
45 334 Persistence of Anti-SARS-CoV-2 IgM Antibody up to 8 Months Post-COVID-19.  
46  
47  
48  
49 335 *Case Rep Clin Med* 2021, 10, 227-231. <https://www.scirp.org/journal/crcm>.  
50  
51  
52 336 13. Omer SB, Yildirim I, Forman HP. Herd Immunity and implications for SARS-  
53  
54  
55  
56 337 CoV-2 control. *JAMA* 2020. <https://doi.org/10.1001/jama.2020.20892>.  
57  
58  
59  
60

- 1  
2  
3  
4 338 14. Buss LF, Prete CA Jr, Abraham CMM, et al. Three-quarters attack rate of SARS-  
5  
6  
7 339 CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. *Science*  
8  
9  
10 340 2020;8:eabe9728. <https://doi.org/10.1126/science.abe9728>.  
11  
12  
13  
14 341 15. Hallal PC, Hartwig FP, Horta BL, et al. SARS-CoV-2 antibody prevalence in  
15  
16  
17 342 Brazil: results from two successive nationwide serological household surveys.  
18  
19  
20  
21 343 *Lancet Glob Health*. 2020;8(11):e1390-e1398. <https://doi.org/10.1016/S2214->  
22  
23  
24 344 109X(20)30387-9.  
25  
26  
27  
28 345 16. Crosby AW. Virgin soil epidemics as a factor in the aboriginal depopulation in  
29  
30  
31 346 America. *William Mary Q*. 1976;33:289-99. PMID: 11633588.  
32  
33  
34  
35 347 17. da Silva HP, Abreu IN, Lima CNC, et al. Migration in times of pandemic: SARS-  
36  
37  
38 348 CoV-2 infection among the Warao indigenous refugees in Belém, Pará,  
39  
40  
41  
42 349 Amazonia, Brazil. *BMC Public Health*. 2021;21(1):1659. doi: 10.1186/s12889-  
43  
44  
45 350 021-11696-7.  
46  
47  
48  
49 351 18. Pontes GS, de Melo Silva J, Pinheiro-Silva R, Barbosa AN, Santos LC, de  
50  
51  
52 352 Pádua Quirino Ramalho A, de Castro Alves CE, da Silva DF, de Oliveira LC, da  
53  
54  
55  
56 353 Costa AG, Bruno AC. Increased vulnerability to SARS-CoV-2 infection among  
57  
58  
59  
60

1  
2  
3  
4 354 indigenous people living in the urban area of Manaus. *Sci Rep.*

5  
6  
7 355 2021;11(1):17534. doi: 10.1038/s41598-021-96843-1.

8  
9  
10 356 19. Walker RS, Sattenspiel L, Hill KR. Mortality from contact-related epidemics

11  
12  
13  
14 357 among indigenous populations in Greater Amazonia. *Sci Rep.* 2015;5:14032.

15  
16  
17 358 <https://doi.org/10.1038/srep14032>.

18  
19  
20  
21 359

22  
23  
24 360 Figure Legend.

25  
26  
27  
28 361 **Figure 1.** Map showing the geographical location of the indigenous communities

29  
30  
31 362 enrolled in the present study.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Map showing the geographical location of the indigenous communities enrolled in the present study.

296x209mm (600 x 600 DPI)

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract <i>Page 1, lines 1 and 2</i>
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found <i>Page 2, lines 26 – 36</i>
<b>Introduction</b>		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported <i>Page 3, lines 55 – 65</i>
Objectives	3	State specific objectives, including any prespecified hypotheses <i>Page 3, lines 66 – 72</i>
<b>Methods</b>		
Study design	4	Present key elements of study design early in the paper <i>Page 4, lines 75 – 81</i>
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection <i>Pages 4 – 6 , lines 84 – 127</i>
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants <i>Pages 4 – 6 , lines 84 – 127</i>
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable <i>Pages 6 and 7 , lines 130 – 134</i>
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group <i>Pages 6 and 7 , lines 84 – 134</i>
Bias	9	Describe any efforts to address potential sources of bias <i>Page 7, lines 136 – 140</i>
Study size	10	Explain how the study size was arrived at <i>Page 7, lines 136 – 140</i>
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why <i>Page 7, lines 136 – 140</i>
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding <i>Page 7, lines 136 – 140</i>
		(b) Describe any methods used to examine subgroups and interactions <i>Page 7, lines 136 – 140</i>
		(c) Explain how missing data were addressed <i>Page 7, lines 136 – 140</i>
		(d) If applicable, describe analytical methods taking account of sampling strategy
		(e) Describe any sensitivity analyses <i>Pages 7, lines 136 – 140</i>
<b>Results</b>		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed

[Pages 7 and 8; lines 147 – 162](#)

(b) Give reasons for non-participation at each stage

[Pages 7 and 8; lines 147 – 162](#)

(c) Consider use of a flow diagram

[Not applicable](#)

Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders <a href="#">Pages 7 and 8; lines 147 – 162</a> (b) Indicate number of participants with missing data for each variable of interest <a href="#">Pages 7 and 8; lines 147 – 162</a>
Outcome data	15*	Report numbers of outcome events or summary measures <a href="#">Pages 7 and 8; lines 147 – 162</a>
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included <a href="#">Pages 7 and 8; lines 147 – 162</a> (b) Report category boundaries when continuous variables were categorized <a href="#">Pages 7 and 8; lines 147 – 162</a> (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period <a href="#">Pages 7 and 8; lines 147 – 162</a>
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses <a href="#">Pages 7 and 8; lines 147 – 162</a>
<b>Discussion</b>		
Key results	18	Summarise key results with reference to study objectives <a href="#">Page 11 – 14; lines 178 - 236</a>
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias <a href="#">Page 13; lines 227 - 228</a>
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence <a href="#">Page 13 – 14; lines 234 - 243</a>
Generalisability	21	Discuss the generalisability (external validity) of the study results <a href="#">Page 12 – 14; lines 203 - 226</a>
<b>Other information</b>		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based <a href="#">Page 14 – 15; lines 256 - 260</a>

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at

1  
2 <http://www.annals.org/>, and *Epidemiology* at <http://www.epidem.com/>). Information on the STROBE Initiative is  
3 available at [www.strobe-statement.org](http://www.strobe-statement.org).  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only